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ABSTRACT 
While several tools have been developed to map axes of variation among individual cells, 
no analogous approaches exist for identifying axes of variation among multicellular 
biospecimens profiled at single-cell resolution. Developing such an approach is of great 
translational relevance and interest, as single-cell expression data are now often collected 
across numerous experimental conditions (e.g., representing different drug perturbation 
conditions, CRISPR knockdowns, or patients undergoing clinical trials) that need to be 
compared. In this work, “Phenotypic Earth Mover's Distance” (PhEMD) is presented as a 
solution to this problem. PhEMD is a general method for embedding a “manifold of 
manifolds,” in which each datapoint in the higher-level manifold (of biospecimens) 
represents a collection of points that span a lower-level manifold (of cells). 
PhEMD is applied to a newly-generated, 300-biospecimen mass cytometry drug 
screen experiment to map small-molecule inhibitors based on their differing effects on 
breast cancer cells undergoing epithelial–mesenchymal transition (EMT). These 
experiments highlight EGFR and MEK1/2 inhibitors as strongly halting EMT at an early 
stage and PI3K/mTOR/Akt inhibitors as enriching for a drug-resistant mesenchymal cell 
subtype characterized by high expression of phospho-S6. More generally, these 
experiments reveal that the final mapping of perturbation conditions has low intrinsic 
dimension and that the network of drugs demonstrates manifold structure, providing 
insight into how these single-cell experiments should be computational modeled and 
visualized. In the presented drug-screen experiment, the full spectrum of perturbation 
effects could be learned by profiling just a small fraction (11%) of drugs. Moreover, 
PhEMD could be integrated with complementary datasets to infer the phenotypes of 
biospecimens not directly profiled with single-cell profiling. Together, these findings 
have major implications for conducting future drug-screen experiments, as they suggest 
that large-scale drug screens can be conducted by measuring only a small fraction of the 
drugs using the most expensive high-throughput single-cell technologies—the effects of 
other drugs may be inferred by mapping and extending the perturbation space.  
PhEMD is also applied to patient tumor biopsies to assess intertumoral 
heterogeneity. Applied to a melanoma dataset and a clear-cell renal cell carcinoma 
dataset (ccRCC), PhEMD maps tumors similarly to how it maps perturbation conditions 
as above in order to learn key axes along which tumors vary with respect to their tumor-
infiltrating immune cells. In both of these datasets, PhEMD highlights a subset of tumors 
demonstrating a marked enrichment of exhausted CD8+ T-cells. The wide variability in 
tumor-infiltrating immune cell abundance and particularly prominent exhausted CD8+ T-
cell subpopulation highlights the importance of careful patient stratification when 
assessing clinical response to T cell-directed immunotherapies. 
Altogether, this work highlights PhEMD’s potential to facilitate drug discovery 
and patient stratification efforts by uncovering the network geometry of a large collection 
of single-cell biospecimens. Our varied experiments demonstrate that PhEMD is highly 
scalable, compatible with leading batch effect correction techniques, and generalizable to 
multiple experimental designs, with clear applicability to modern precision oncology 
efforts. 
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Bulk vs. single-cell profiling 
Next-generation sequencing (NGS) has revolutionized the way in which diseases can be 
studied. Bulk DNA sequencing (DNA-seq) of germline biospecimens can be leveraged to 
discover disease-specific polymorphisms and to investigate disease heritability at an 
unprecedented scope and level of detail (1–3). In the setting of cancer, bulk DNA-seq of 
liquid- or solid-tumor biopsies has been used to identify somatic alterations (e.g., 
mutations, copy number alterations, and structural variants) that can serve as biomarkers 
prognostic of clinical outcomes and predictive of response to therapies (4–9). 
Complementarily, bulk RNA-sequencing (RNA-seq) has been used to quantitate gene 
expression of protein-coding genes and long non-coding RNAs at the exon level of 
resolution. Paired with proteomic assays, NGS approaches have facilitated our 
understanding of cellular biology and genomic drivers of disease at all steps of the central 
dogma, from DNA to RNA to protein. 
 While instrumental in building our foundational understanding of cancer 
genomics, bulk tumor profiling faces the notable limitation of being unable to resolve 
intratumoral heterogeneity. By nature of the sample preparation procedure for bulk NGS, 
DNA or RNA fragments are isolated from all cells of a biospecimen in aggregate, and 
per-cell read counts cannot be determined. Thus, genomic variants identified via bulk 
DNA-seq can only be interpreted as being present in some fraction of profiled cells. 
Moreover, it is impossible to determine which of the variants co-occur in a given cancer 
cell. The readout of bulk RNA-seq is similarly coarse in that the reported expression of a 
given gene represents the average expression across all cells in the biospecimen without 
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any consideration of cell-to-cell variation. In practice, when comparing expression values 
across biospecimens measured using bulk profiling or when performing association 
studies between specific DNA variants and clinical phenotypes, a simplifying assumption 
is often made that all (or at least a substantial-enough proportion of) cells in each 
biospecimen harbor the genomic variant or gene expression signature of interest. In 
reality, this assumption may not always be valid, and bulk measurements may fail to 
accurately reflect the expression profiles of individual cells. Bulk profiling may also fail 
to detect true biological differences between experimental conditions.  The following 
example demonstrates these concepts more concretely and highlights the utility of single-
cell analytical approaches for accurately characterizing and distinguishing between 
multicellular biospecimens.  
Consider a multi-specimen dataset consisting of immune cells with collectively 
variable expression of CD4 and CD8. Each specimen is comprised of a cell population 
that fits one of four distribution patterns, as shown below (Figure 1A). Each Group A 
specimen consists of a homogeneous immune cell population characterized by 
intermediate expression of both CD4 and CD8. Each Group B specimen consists of two 
similarly-abundant immune cell subpopulations: one CD4+ and one CD8+ subpopulation. 
Group C specimens consist of a mixture of CD4+, CD8+, and CD4/CD8 double-positive 
(DP) immune cells. Group D specimens consist of one CD4+ and one CD8+ 
subpopulation of roughly equal abundance and one additional rare subpopulation of 
CD4/CD8 double-negative (DN) immune cells. Note that these immune cell subtypes 
(CD4+, CD8+, DP, and DN) have been reported to exist in normal thymus as well as 
various disease states (e.g., breast and hematologic malignancies (10, 11)). The simulated 
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experiment consists of 32 specimens in total (eight of each of Groups A-D). By design, 
the bulk (average) expression of CD4 and CD8 for each biospecimen is roughly the same 
for all biospecimens, regardless of differences in cell subpopulation characteristics. 
 
Figure 1. a) Single-cell profiles of each multicellular biospecimen in a computationally-generated immune 
cell dataset. Each point represents a single cell. Groups A-D each have 8 biospecimens that fit the single-
cell profile (i.e., are comprised of some combination of the cell subpopulations depicted) for a total of 32 
biospecimens. By design, all biospecimens have roughly the same bulk expression (mean across all cells) 
of CD4 and CD8. b) Diffusion map embedding generated by embedding a specimen-to-specimen distance 
matrix, where pairwise distances between specimens were computed by taking the Euclidean distance 
between specimens represented as bulk expression of CD4 and CD8. Bulk expression profiles do not 
adequately reflect the biological differences between specimens in this dataset and cannot be used to 
distinguish specimens in a biologically meaningful way. c) Diffusion map embedding generated by 
embedding a PhEMD distance matrix, which accounts for the single-cell characteristics of each specimen 
(see “Overview of PhEMD” in Results section). PhEMD successfully distinguishes specimens with 
different single-cell profiles from one another.  
Next, consider the aim of relating the 32 specimens to one another in a 
biologically meaningful way. This could be done by generating a low-dimensional 
embedding that could be visualized to view the similarity of any two specimens relative 
to the rest and to identify groups of similar biospecimens. First, consider an approach 
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using bulk expression measurements. A biospecimen–biospecimen distance matrix can be 
generated by computing pairwise (Euclidean) distances between each pair of 
biospecimens, with each biospecimen represented as the average expression of each gene 
(i.e., CD4 and CD8) across all cells in the biospecimen. This distance matrix can then be 
embedded and visualized in two dimensions using the diffusion map nonlinear 
dimensionality reduction approach. The result is an embedding that fails to differentiate 
specimens based on biologically important differences. Specifically, specimens of the 
same known, ground-truth subtype (i.e., Group A-D) failed to map to similar parts of the 
resulting embedding (Figure 1B). 
A better approach to comparing these specimens is to compare the presence and 
abundance of all single-cell subpopulations in each specimen. I aim to formalize such an 
approach in this thesis and demonstrate that it can be used to effectively distinguish 
single-cell specimens from one another that cannot be distinguished based on bulk or 
average expression patterns. In the above example, the approach yields a final low-
dimensional map that vastly outperforms a bulk approach (Figure 1B) and successfully 
differentiates specimens based on biologically important differences in cell subpopulation 
characteristics and proportions (Figure 1C).  
 The exploration of cell-to-cell variation within a given biospecimen has been 
facilitated by the recent development of single-cell expression profiling (measurement of 
gene expression on a per-cell rather than average-across-all-cells level). Early studies 
leveraging these technologies have uncovered important insights not previously identified 
by bulk profiling. Several studies have highlighted the compositional heterogeneity of 
tumors as a mixture of specific cancer and non-malignant (e.g., immune and stromal) cell 
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types and have revealed profound cellular heterogeneity among melanoma (12), clear-cell 
renal cell carcinoma (ccRCC) (13), and breast cancer cells (14), even within a single 
tumor biopsy. Additional studies have used single-cell profiling to better elucidate cell 
signaling, differentiation, and reprogramming in the context of cancer (15), aging (16), 
and other physiologic and disease processes (17–19). Among else, single-cell profiling is 
particularly useful for studying cancer, as cancer is understood to arise from the genomic 
mis-programming of a single cell and the downstream sequelae. While the analytical 
approaches presented in this work are generalizable to studying many biological 
phenomena at a single-cell level, the focus of this thesis will be on leveraging single-cell 
technologies to better understand cancer progression, cellular response to 
chemotherapies, and the tumor microenvironment. 
Approaches to characterizing axes of variation among a collection of cells 
As the readout of single-cell expression profiling is highly complex, new computational 
tools have been developed in parallel with single-cell profiling techniques in order to 
facilitate the extraction of biological insights. A particularly challenging property of 
single-cell expression data is its high dimensionality: each biospecimen is comprised of 
many cells, each of which is represented by tens to thousands of gene or protein 
measurements. The analysis of high-dimensional data, especially in unsupervised or 
exploratory settings, often introduces various challenges that are collectively referred to 
as the “curse of dimensionality” (20, 21). While the ambient dimension of single-cell data 
is often high (equal to the number of genes or proteins measured), the intrinsic 
dimension, or minimum number of variables needed to represent the data adequately, is 
often much lower. Mapping single-cell data from its ambient dimension to this lower-
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dimensional space is termed “dimensionality reduction,” which is often a critical first 
step for learning and visualizing the ways in which cells vary. It is also instrumental in 
identifying distinct, biologically meaningful cell subpopulations (e.g., by clustering cells 
in the lower-dimensional space). The following subsections provide an overview of 
several of the leading dimensionality reduction techniques for learning and visualizing 
axes of cell-to-cell variation among a set of cells measured using single-cell expression 
profiling. In the below subsections, each “dataset” refers to a heterogeneous cell 
population and each “point” represents a single cell, characterized by multiple measured 
features (i.e., gene expression values). 
Principal Component Analysis (PCA) 
Principal component analysis (PCA) is a dimensionality reduction technique that aims to 
find new, uncorrelated variables (“principal components”) that successively maximize 
variance while minimizing information loss from the original dataset (22). It does so by 
performing an orthogonal transformation of the original dataset such that the new 
variables are linear combinations of features in the original ambient-dimensional space. 
This transformation can be computed as the solution to an eigenvalue/eigenvector 
problem, in which principal components are defined as eigenvectors of the covariance 
matrix and corresponding eigenvalues represent the proportion of the data variance 
explained by the eigenvectors.  
PCA is useful in many settings for learning a low-dimensional representation of 
the data, although it does make several key assumptions. Firstly, it assumes that the 
principal components are appropriately modeled as linear combinations of the original 
dimensions. Secondly, PCA assumes that principal components are orthogonal to one 
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another. Thirdly, PCA assumes that the input data are scaled and normalized 
appropriately prior to application, as the approach is not scale invariant. In the event that 
any of these assumptions are violated, PCA may fail to recover optimal axes of variation 
in the data. Additionally, by design, PCA prioritizes preserving global structure (i.e., 
distances between faraway points) over local structure (i.e., distances between points 
within the same “neighborhood”) when mapping from high- to low-dimensional space. 
Thus, the approach is especially sensitive to outliers and measurement noise. 
t-Distributed Stochastic Neighbor Embedding (t-SNE) 
t-Distributed Stochastic Neighbor Embedding (t-SNE) is a popular dimensionality 
reduction approach that preserves local relationships between points when mapping them 
from an ambient-dimensional to low-dimensional space (23). Put another way, points that 
are close to one another in the original representation of the data are mapped to be close 
to one another in the final low-dimensional t-SNE space. Consider two points i and j 
denoted by xi and xj respectively in the ambient-dimensional space and yi and yj 
respectively in the low-dimensional space. t-SNE first models each point in the ambient-
dimensional space as a Gaussian probability distribution centered on the actual 
coordinates of the point (with a data-dependent variance proportional to a user-specified 
“perplexity” value), then computes pairwise similarity between points xi and xj as the 
conditional probability Pj|i that xi would select xj as its neighbor if neighbors were 
selected in proportion to their probability density under a Gaussian centered at xi (24). An 
analogous conditional probability Qj|i is computed between points yi and yj in the low-
dimensional t-SNE space, wherein points yi and yj are modeled as Student t-distribution 
with one degree of freedom (rather than as a Gaussian distribution). The final low-
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dimensional embedding is learned through gradient descent by minimizing the Kullback-
Leibler (KL) divergence between P and Q. In the perfect case, the difference between Pj|i 
and Qj|i is zero for all i and j, i.e., the pairwise relationships between points are perfectly 
preserved in the ambient and t-SNE dimensions.  
Strengths of t-SNE include non-linearity, which renders it superior to linear 
approaches such as PCA when applied to curved manifolds, and preservation of local 
structure, which reveals subtle differences between similar yet distinct cell 
subpopulations. A limitation of t-SNE is its high computational resource demands. In its 
exact form, t-SNE has a quadratic time and space complexity, making applications to 
datasets larger than 10,000 points often computationally intractable. To mitigate this 
issue, various approximations and optimizations have been developed (25–27). Another 
limitation is the loss of global structure preservation in the final embedding. t-SNE 
effectively identifies neighborhoods of points but generally yields disjoint “clouds” of 
points. Thus, continuous (e.g. cellular differentiation) processes and trajectories are often 
fragmented in the t-SNE embedding, and relative distances between faraway points or 
clusters in the embedding are not preserved (28).  
Uniform Manifold Approximation and Projection (UMAP) 
Uniform Manifold Approximation and Projection (UMAP) is a dimensionality reduction 
approach that has been recently popularized due to its purported advantages over t-SNE 
in terms of improved scalability and preservation of both local and global data structure 
(29). Similarly to t-SNE, UMAP models points as probability distributions and performs 
gradient descent to iteratively “move” points more similar to one another in the ambient-
dimensional space to be closer to one another in the low-dimensional embedding. 
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However, among other minor differences, UMAP omits the normalization of probabilities 
used in t-SNE (thus improving runtime) and uses binary cross-entropy instead of KL 
divergence as the cost function when comparing relationships between points in the 
ambient-dimensional and low-dimensional spaces. UMAP also employs a graph 
Laplacian approach to assigning the initial coordinates of the points in low-dimensional 
space (prior to the first iteration of gradient descent), in contrast to the random 
initialization employed by t-SNE. Early studies have claimed advantages of UMAP over 
t-SNE in terms of faster computational runtime, greater preservation of global data 
structure, and increased reproducibility of results across different iterations. However, 
there is ongoing debate as to whether global structure is truly better preserved using 
UMAP than t-SNE and if so, why exactly this may be (30). 
Tree-based approaches 
Several graph-based approaches have been developed to explicitly model single-cell 
expression datasets as an interconnected “web” or “tree” of cells. Particularly aimed at 
organizing and visualizing data with intrinsic trajectory structure (e.g., bifurcating 
differentiation processes), these approaches typically represent cells as nodes and 
relationships between similar cells as edges between nodes. Distances between cells can 
then be defined as the shortest path between representative nodes (i.e., minimum number 
of edges separating one cell from the other or, in the event of weighted edges, minimum 
sum of edge lengths in a path from one cell to the other). Several particular single-cell 
tools that employ such an approach include SPADE (31), Wishbone (32), and Monocle2 
(33). These approaches are particularly useful for modeling continuous manifolds and for 
resolving local neighborhood structure. A key limitation of most tree-based approaches is 
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poor scalability. In practice, when working with large datasets, these approaches often 
require cell subsampling or prior identification of “landmark points” which may then 
collectively comprise a relatively small number of graph nodes. Additionally, the number 
of branches recovered in the final tree can vary greatly and is often dependent on user-
defined parameters, which may be challenging to tune if the expected number of branches 
is not known a priori. 
Diffusion maps 
Diffusion maps are another nonlinear dimensionality reduction technique based on the 
idea that a collection of points (e.g., cells) may be modeled such that a given point (e.g., 
cell) may “transition” to another point (e.g., similar cell state) with a probability 
proportional to the known similarity of the two points (34). Diffusion maps first model 
points as an interconnected graph, with connectivity between points generally based on 
their distance in the ambient-dimensional space (e.g., Gaussian kernel, which prioritizes 
preservation of local neighborhood structure). The point-to-point connectivity metric is 
then used to represent the probability of “transitioning” from one cell to another in one 
step of a random walk. A diffusion process is then performed over a diffusion time t (i.e., 
t-step random walk), wherein the local connectivity of the data is used to reveal the 
global geometric structure of the data. The end result is a set of t-step transition 
probabilities, which can be used to embed a low-dimensional map that captures both local 
and global structure in the data. Diffusion maps are particularly well-suited for modeling 
single-cell datasets with known trajectory structure and are modeled on underlying 
principles that reflect our intuitive understanding of cellular differentiation processes 
(e.g., “transition” from one cell state to the next). Diffusion maps are also attractive for 
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their nonlinearity and inherent denoising properties. Limitations of diffusion maps 
include high computational runtime and sensitivity to scale parameter σ, which 
determines the scale at which the data are visualized (35). In the traditional 
implementation of diffusion maps, a fixed σ is used for all points in the dataset, often 
imposing a tradeoff between preserving global and local structure with a bias toward 
preserving global structure (34, 35). However, subsequent adaptations to the original 
implementation proposed by Coifman and Lafon have been developed to better preserve 
local structure (36).  
PHATE 
Potential of Heat-diffusion for Affinity-based Transition Embedding (PHATE) is a 
nonlinear dimensionality reduction technique that aims to preserve both local and global 
structure when mapping from high- to low-dimensional space (37). Similarly to diffusion 
maps, PHATE models cell-to-cell connectivity as one-step transition probabilities in a 
random walk model and then performs the diffusion process over diffusion time t to 
determine t-step transition probabilities. However, PHATE employs a distance metric 
(“potential distance”) between points in the diffusion space distinct from the “diffusion 
distance” metric used in diffusion maps. In so doing, PHATE better preserves both local 
and global data geometry and yields a more stable embedding than diffusion maps (37). 
Characterizing axes of variation among a collection of multicellular cancer 
specimens 
The multitude of dimensionality reduction techniques described above have been adopted 
and adapted to elucidate clusters, patterns, and progressions from high-dimensional 
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single-cell data. These techniques all rely on the ability to create a geometry from 
datapoints by comparing them on the basis of their features. More specifically, these 
techniques often compute a distance between the datapoints (i.e., cells) in order to 
organize cells into lower-dimensional embeddings, such as diffusion maps or t-SNE 
embeddings, in order to extract biologically meaningful clusters (i.e., cell subtypes) or 
trajectories (e.g., cell differentiation pathways) from the data. 
However, single-cell experimental designs are becoming increasingly complex, 
with data now often collected across numerous experimental conditions to characterize 
libraries of drugs, pools of CRISPR knockdowns, or groups of patients undergoing 
clinical trials (12, 13, 38–42). The challenge in these experiments is to characterize the 
ways in which not only individual cells but also multicellular experimental conditions 
vary. Comparing single-cell experimental conditions (e.g., distinct perturbation 
conditions or patient samples) is challenging, as each condition is itself high-dimensional, 
comprised of a heterogeneous population of cells with each cell characterized by many 
gene measurements. Each “datapoint” in such settings should then be a patient or an 
experimental condition, which has a collection of measurements associated with it instead 
of a single measurement. In this setting, a datapoint is no longer a single set of features 
(i.e., a vector) but a collection of observations, each containing its own features (i.e., a 
two-dimensional matrix). Thus, existing techniques can no longer be directly applied for 
analysis in a straightforward manner. 
While two prior studies presented approaches to comparing two single-cell 
biospecimens (43, 44), no existing methods address the problem of simultaneously 
relating many biospecimens and identifying biologically meaningful ways in which they 
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differ. In this work, Phenotypic Earth Mover’s Distance “PhEMD” is presented as a novel 
“manifold-of-manifolds” approach to mapping the key axes of variation among a large 
set of experimental conditions. PhEMD first leverages the observation that the structure 
of a single-cell experimental condition (i.e., multicellular biospecimen) can be well 
represented as a low-dimensional manifold (i.e., cell-state embedding) using techniques 
such as PHATE or diffusion maps. In this first-level manifold, individual datapoints 
represent cells, and distances between cells represent cell-to-cell dissimilarity. PhEMD 
models the cellular state space of each experimental condition as a “low-level” manifold 
and then models the experimental condition state space as a “higher-level” manifold. The 
ultimate goal of PhEMD is to generate this higher-level manifold, in which each 
datapoint represents a distinct experimental condition and distances between points 
represent biospecimen-to-biospecimen dissimilarity. In this work, the properties and 
potentially applications of this final higher-level manifold are explored in depth. Namely, 
the manifold can be visualized and clustered to reveal the key axes of variation among a 
large set of experimental conditions. Such embeddings can also be extended with 
additional data sources to impute experimental conditions not directly measured with 
single-cell technologies. 
The accuracy of PhEMD is first validated on a synthetic dataset with known 
underlying data geometry. PhEMD is then applied to a newly-generated single-cell 
dataset to reveal insights into cancer progression and cancer drug-perturbation effects. 
Specifically, the dataset represents a large perturbation screen performed on breast cancer 
cells undergoing TGFb1-induced epithelial-to-mesenchymal transition (EMT), measured 
at single-cell resolution with mass cytometry. EMT is a process that is thought to play a 
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role in cancer metastasis, whereby polarized epithelial cells within a local tumor undergo 
specific biochemical changes that result in cells with increased migratory capacity, 
invasiveness, and other characteristics consistent with the mesenchymal phenotype (45). 
In the drug-screen experiment, each perturbation condition consists of cells from the 
Py2T breast cancer cell line stimulated simultaneously with TGF-b1 (to undergo EMT) 
and a unique kinase inhibitor, with the ultimate goal being to compare the effects of 
different inhibitors on our model EMT system. PhEMD is used to embed the space of the 
kinase inhibitors to reveal the main axes of variation among all inhibitors with respect to 
their effects on breast cancer cells undergoing EMT. Reproducibility of results is assessed 
through three biological replicates. Additionally, the drug-effect findings are further 
validated by showing that they are consistent with the drug-effect findings of a previously 
published study that profiled the drug-target binding specificities of several of the same 
drugs as those used in the present drug-screen experiment. 
PhEMD is also applied to two distinct single-cell datasets to reveal insights into 
variation in the immune cell infiltrate of solid tumors profiled with single-cell resolution. 
The first dataset consists of a collection of 17 melanoma samples profiled using single-
cell RNA-sequencing (scRNA-seq) and the second is comprised of 75 clear-cell renal cell 
carcinoma (ccRCC) samples profiled using mass cytometry. These experiments yield a 
low-dimensional map of patient tumors that highlights profound inter-tumoral 
heterogeneity with respect to tumor-infiltrating immune cells, demonstrating the potential 
utility of PhEMD for disease subtyping and patient stratification (e.g., for immunotherapy 
trials or clinical outcomes studies). Collectively, the analyses present a new generalizable 
analytical framework for organizing single-cell data and reveal new potential strategies 
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for identifying effective cancer therapies. 
 
Hypothesis 
A “manifold-of-manifolds” approach to modeling multi-specimen single-cell data can 
accurately identify axes of variation among biospecimens and simultaneously reveal 
insights into both intra- and inter-specimen heterogeneity.  
 
Specific Aims 
Aim 1: Develop a robust tool for uncovering axes of variation among single-cell 
biospecimens 
Aim 2: Characterize the differing effects of 233 small-molecule inhibitors on breast 
cancer epithelial–mesenchymal transition (EMT) 
Aim 3: Characterize the immune cell subpopulational variation among melanomas and 
among clear-cell renal cell carcinomas (ccRCCs) 
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MATERIALS AND METHODS 
The PhEMD analytical approach 
In single-cell data, each cell is characterized by a set of features, such as protein or 
transcript expression levels of genes. The purpose of measuring these expression-based 
features for each cell (e.g., via single-cell RNA-seq or mass cytometry) is to answer 
biological questions especially related to the cell subpopulations present in a 
biospecimen. In particular, the features may be used for defining phenotypes of cells  (38, 
46), resolving cellular dynamics using transition-process modeling (32, 33, 47), and 
studying signaling networks (18, 48). In sum, the features are shared, quantitative 
characteristics of cells that may be used to organize a set of cells into a data geometry. An 
analogy can be made when attempting to compare single-cell specimens rather than 
individual cells. A biospecimen is a collection of cells. In order to compare single-cell 
biospecimens for the purpose of organizing a set of cell collections (e.g., different patient 
specimens or perturbation conditions), one must first determine useful features for a cell 
collection. Previous studies have shown that cell subtypes are highly useful features that 
are shared across all specimens and can be quantitatively measured (46, 49). Moreover, 
they can be used to represent single-cell specimens efficiently for downstream analyses. 
Just as transcript counts can be measured for selected genes in a single cell, so can cell 
counts be measured for selected cell subtypes in a cell collection. 
In the present work, PHATE is used for the task of defining cell subtypes (37). 
PHATE is a diffusion-based single-cell dimensionality reduction technique that both 
identifies unique cell subpopulations and relates them to one another on a low-
dimensional manifold that can be visualized. Of note, PHATE preserves an information 
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theoretic distance between points (i.e., cells) in the diffusion space to derive a stable low 
dimensional embedding that reveals local, global, continual, and discrete non-linear 
structures in single-cell data. By applying PHATE to an aggregate of cells in a single-cell 
experiment, we can represent a biospecimen as the relative frequency of cells in each cell 
subtype. This representation of single-cell specimens is consistent with the “signatures-
and-weights” representation of multidimensional distributions, first formalized by Rubner 
et al. (50), that was found to yield optimal data representation efficiency in other 
computer vision applications. In our case, a “signature” can be thought of as a distinct 
cell subtype (e.g., memory B-cells or CD8+ effector T-cells), and the corresponding 
“weight” represents the proportion of cells in a given specimen assigned to the cell 
subtype. However, comparing single-cell specimens represented as such is still a non-
trivial task. Many studies represent single-cell specimens as their cell subtype 
composition and use known class labels (e.g., normal lung vs. lung adenocarcinoma) to 
group specimens and perform class-based comparisons (e.g., identifying cell subtypes 
enriched in a disease state) (39, 40). However, this approach is limited to comparing a 
few predefined classes of specimens and does not reveal insights into intra-class 
heterogeneity. Other studies organize a set of many single-cell specimens based on their 
relative frequency of one or a few important cell subtypes (41, 46, 51). However, this 
approach requires a priori knowledge of the most important cell subtypes and does not 
provide a complete view of specimen-to-specimen dissimilarity, especially in the context 
of high intra-specimen cellular heterogeneity. 
The ideal metric for comparing specimens should take into account both the 
difference in weights of matching bins (e.g., number of epithelial cells) for all bins and 
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the dissimilarity of the bins themselves (e.g., intrinsic dissimilarity between epithelial and 
mesenchymal cells). As a simple example using the EMT model, for a specimen with 
80% mesenchymal, 10% transitional, and 10% epithelial cells, we would expect a 
specimen with 50% mesenchymal, 40% transitional, and 10% epithelial cells to be more 
similar (closer in distance) than a specimen with 50% mesenchymal, 10% transitional, 
and 40% epithelial cells. This would be consistent with our intuitive sense of distance 
because 80-10-10 represents that most cells have fully transitioned from epithelial to 
mesenchymal states, 50-40-10 represents that most cells have partly or fully transitioned, 
and 50-10-40 represents that almost half of the cells have not transitioned at all. Earth 
Mover’s Distance (EMD) is a distance metric that mathematically encodes this intuition 
and can be used to yield a final singular measure of distance, or dissimilarity, between 
two specimens (50). EMD can be conceptualized as the minimal amount of “effort” 
needed to move mass (e.g., cells) between bins of one histogram so that its shape matches 
that of the other histogram (i.e., all matching bins of two histograms have the same 













Such that ∑ ∑ +,-.,-/-012,01  is minimized subject to the following constraints: 
1) +,- ≥ 0   1 ≤ 7 ≤ 8,  1 ≤ 9 ≤ : 
2) ∑ +,-/-01 ≤ ;<=   1 ≤ 7 ≤ 8 
3) ∑ +,-2,01 = ;>?   1 ≤ 9 ≤ : 
Definition 1. Earth Mover’s Distance as an optimization problem. 
P = {(p1, ;<@), … , (pm, ;<A)}, where pi represents histogram bin i in the initial starting 
signature P and ;<=  represents the amount of “mass” present in bin i. Similarly, 
Q = {(q1,	;>@), … , (qn, ;>C)}, where qj represents histogram bin j in the final signature Q 
and ;>?  represents the amount of “mass” present in bin j. +,-  represents the “flow” or 
amount of mass moved from bin pi to bin qj. .,- represents the “ground distance” 
between bins pi and qj. Constraint 1 ensures that P and Q are the starting and final 
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signatures, respectively. Constraints 2 and 3 ensure that no more mass is moved from any 
bin pi than is present initially.  
EMD has been used in various applications including image retrieval (50, 52), 
visual tracking (53), and melodic similarity musical analysis (54): all tasks that require 
accurate comparison of multidimensional distributions (analogous to comparing single-
cell specimens). Additionally, a prior study demonstrated proof-of-concept that Earth 
Mover’s Distance can be used effectively to differentiate flow cytometry specimens of 
phenotypically distinct individuals (55). By design, EMD is a distance measure between 
probability distributions that is particularly invariant to small shifts in data (i.e., noise or 
technical variability) across specimens (50, 55). EMD also gives a “complete” measure of 
overall dissimilarity between two specimens, largely attributable to the fact that it takes 
into account both the difference in height of corresponding histogram bins between 
specimens (e.g., number of epithelial cells) and the concept that certain bins (e.g., cell 
subtypes) have a smaller “ground distance” (i.e., are more similar) than others. Including 
ground distance between bins in the EMD computation allows us to incorporate the idea 
that it requires more “effort” to move mass to a faraway bin than to a nearby bin (i.e., it 
requires more effort to convert cells to a more dissimilar cell signature than to a more 
similar cell signature). Recall that each cell subtype is associated with various different 
datapoints (individual cells assigned to that subtype), so it can be represented as the 
centroid of the cluster of cells that comprise it. In our application, we define the ground 
distance between two cell subtypes as the manifold distance between the cluster centroids 
of the two cell subpopulations representing the subtypes. 
EMD is used to compare a pair of single-cell specimens, but the issue remains of 
how to relate a large set of samples simultaneously. For this task, we employ a manifold 
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learning approach that assumes the intrinsic geometry of the data can conceptually be 
modeled as a low dimensional manifold (i.e., a collection of smoothly-varying, locally 
low-dimensional data patches), which is derived from the high-dimensional ambient 
space of collected features (56). Such methods aim to uncover this intrinsic geometry by 
first capturing local neighborhoods, then using them to form a rigid structure of nonlinear 
relations in the data, and finally embedding this structure in a low-dimensional (e.g., 2D 
or 3D) space via a new set of features that preserve those relations (e.g., as distances). 
Local neighborhood (and subsequently global network) structure is learned by first 
computing EMD between each pair of single-cell specimens; distances between “nearby” 
specimens are then preserved in the final learned manifold. 
Leveraging the properties of EMD and manifold learning, we developed PhEMD 
as a novel “manifold-of-manifolds” approach to simultaneously relating a large set of 
single-cell specimens (Figure 2). PhEMD first aggregates cells from all biospecimens and 
applies a single-cell embedding technique (e.g., PHATE) to model the cell-state space 
(i.e., “first-level manifold”). PHATE simultaneously identifies all cell subtypes and 
relates them in a low-dimensional embedding. After constructing the PHATE cell-state 
manifold, PhEMD represents each biospecimen to be compared as a frequency histogram 
capturing relative abundance of each cell subtype (i.e., distribution of cells along a 
manifold). In the event that subsampling is performed when constructing the PHATE 
cell-state manifold, cells are assigned to a subtype using a nearest-neighbor approachA. 
PhEMD then uses EMD, incorporating manifold-distance as ground-distance between 
                                               
ATo assign cell x, which is not initially included in the construction of the PHATE cell-state embedding, to 
a cell subtype, we first identify cell y in the initial embedding that was most similar to cell x, i.e. the cell 
with the lowest Euclidean distance from cell x. Cell x is then given the same cell subtype assignment as cell 
y. 
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bins, to compare two relative abundance histograms and derive a single value 
representing the dissimilarity between two single-cell specimens. PhEMD computes 
EMD pairwise for each pair of specimens to generate a distance matrix representing 
specimen–specimen dissimilarity. Finally, using this distance matrix, PhEMD generates a 
low-dimensional embedding of single-cell specimens (i.e., “higher-level manifold”) using 
diffusion maps to highlight specimen–specimen relationships in the context of overall 
network structure (57). Diffusion maps are useful in this case as they learn a nonlinear 
mapping of samples from high- to low-dimensional space, capture both local and global 
structure, and have intrinsic denoising properties. PhEMD identifies and visualizes 
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Figure 2. a) Flow diagram outlining the sequential steps performed in the PhEMD analysis pipeline. b) 
Schematic of the EMD computation, which accounts for both the differences in heights of matching bins 
and the intrinsic similarity of bins. c) Visual representation of “ground distance” (dissimilarity) between 
cell subtypes. The ground distance between subtypes C-2 and C-6 can be conceptualized as the length of 
the dotted path drawn in grey. 
 
Pseudocode for the PhEMD algorithm is shown below in Algorithm 1. 
Algorithm 1  
1: procedure PhEMD(multispecimen.data)    
⊳Map first-level manifold (e.g., cell-state embedding) 
2: data.all←aggregateData all specimens(multispecimen.data) 
3: first.level.embedding←embedDatapoints(data.all) 
4: first.level.clusts←clusterPoints(first.level.embedding) 
5: cluster.ground.dists←computeGroundDists(first.level.embedding; first.level.clusts)  
	
⊳Map higher-level manifold (e.g., single-cell specimen embedding)  
6: specimen.clus.prop←GetClusterProportions(data.all; first.level.embedding; first.level.clusts)  
7: for each pair of specimens si; sj do  
8: Dists[i; j]←EMD(cluster.ground.dists; specimen.clus.prop[i]; specimen.clus. prop[j])  
9: specimen.embedding←DiffusionMap(Dists)  
10: specimen.clusters←ClusterSpecimens(Dists)  
 
Data collection and processing 
Py2T cell culture and stimulation 
Py2T murine breast cancer cells were obtained from the laboratory of Gerhard 
Christofori, University of Basel, Switzerland (58). Cells were tested for mycoplasma 
contamination upon arrival and regularly during culturing and before being used for 
experiments. Cells were cultured at 37°C in DMEM (Sigma Aldrich), supplemented with 
10% FBS, 2 mM L-glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin, at 5% 
CO2. For cell passaging, cells were incubated with TrypLE Select 10X (Life 
Technologies) in PBS in a 1:5 ratio (v/v) for 10 minutes at 37°C. 
Human recombinant TGF-b1 was purchased from Cell Signaling Technologies as 
lyophilized powder and was reconstituted in PBS containing 0.1% carrier protein, 
according to the manufacturer’s protocol to 400 ng/mL. The stock solution was kept at -
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20°C until use. For daily treatment, TGF-b1 stock was diluted into medium to 40 ng/mL 
working concentration. Following small-molecule inhibitor treatment, 10 µL TGF-b1 was 
added to the cells for a final concentration of 4 ng/mL. As a control, PBS containing 
carrier protein diluted with growth medium was used. 
Small-molecule inhibitors 
A library of 234 small molecule kinase inhibitors was purchased from Selleckchem 
(Table S1). Small-molecule inhibitors were distributed within the 60 inner wells of five 
separate 96-well format deep well blocks with exception of wells within row E, which 
contained DMSO. Stock solutions of 2 mM small molecule inhibitor in DMSO were kept 
at -80°C until used. For daily treatment, the stock solution was equilibrated at room 
temperature for 1 h and then 5 µL of stock solution was added 995 µL of medium. Small-
molecule inhibitor (or DMSO) was added to cells once per day, immediately after the cell 
growth media change and before application of TGF-b1. Small-molecule inhibitor 
treatment was performed by adding 10 L of pre-diluted reagent to the cells in 80 µL cell 
growth medium; this resulted in a final concentration of 1 µM of small-molecule inhibitor 
and 0.1% DMSO. 
Chronic kinase inhibition screen 
For the chronic inhibition experiment, Py2T cells were seeded in 96-well plates (TPP, 
Techno Plastic Products AG) with a seeding density of 1800 cells per well in 80 µL of 
growth cell media. Only the 60 inner wells were used for analysis. In order to acquire 
sufficient sample size, five 96-well plates were used for single condition. After seeding, 
cells were allowed to recover for 36 hours to reach 50% confluence. Cells were treated 
simultaneously with TGF-b1 or vehicle (PBS) and small-molecule inhibitor or vehicle 
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(DMSO) for 5 days, and medium was changed daily. All pipetting procedures were 
performed at room temperature using a Biomek FX Laboratory Automation Workstation 
(Beckman Coulter) supplied with 96-well pipetting pod. 
In addition to experimental conditions treated with small-molecule inhibitors, at 
least five “uninhibited” control conditions and five “untreated” control conditions were 
included on each 96-well plate. Uninhibited control conditions were those in which TGF-
b1 was applied to induce EMT in absence of any inhibitor. Untreated control conditions 
were those in which neither TGF-b1 nor inhibitor was applied and no EMT was induced. 
Cell collection 
The cell collection protocol was performed using a Biomek FX Laboratory Automation 
Workstation. The cell growth medium was removed using the multiple aspiration 
pipetting technique, and cells were washed twice with 37°C PBS. Dissociation reagent 
TrypLE Select 10X (Life Technologies) was diluted into PBS at a 1:5 ratio (v/v) was 
added to the cells and incubated for 10 min at 37°C. Cells were detached from plates. 
Five identically treated 96-well plates were combined into a single deep well block and 
were fixed for 10 min with PFA at the final concentration of 1.6% v/v. PFA was blocked 
with the addition of 600 µL 10% BSA in CSM. The cells were centrifuged for 5 min at 
1040g, at 4°C. The supernatant was removed and the cells were resuspended in 300 µL of 
-20°C MeOH. Samples were then transferred onto dry ice and to -80°C storage. 
Metal-labeled antibodies 
Antibodies were obtained in carrier/protein free buffer and labeled with isotopically pure 
metals (Trace Sciences) using MaxPAR antibody conjugation kit (Fluidigm) according to 
the manufacturer’s standard protocol. After determining the percent yield by 
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measurement of absorbance at 280 nm, the metal-labeled antibodies were diluted in 
Candor PBS Antibody Stabilization solution (Candor Bioscience GmbH) for long-term 
storage at 4°C. Antibodies used in this study are listed in Table S2. 
Mass-tag cellular barcoding and antibody staining 
Cell samples in methanol were washed three times with Cell Staining Media (CSM, PBS 
with 0.5% BSA, 0.02% NaN3) and once with PBS at 4°C. The cells were then 
resuspended at 1 million cells/mL in PBS containing barcoding reagents (102Pd, 104Pd, 
105Pd, 106Pd, 108Pd, and 110Pd; Fluidigm) were conjugated to bromoacetamidobenzyl-
EDTA (BABE, Dojindo) and two indium isotopes (113In and 115In, Fluidigm) were 
conjugated to 1,4,7,10-tetraazacy-clododecane-1,4,7-tris-acetic acid 10-maleimide 
ethylacetamide (mDOTA, Mycrocyclics) following standard procedures. Cells and 
barcoding reagent were incubated for 30 min at room temperature. Barcoded cells were 
then washed three times with CSM, pooled and stained with the metal-conjugated 
antibody mix (Table S2) at room temperature for 1 hour. Unbound antibodies were 
removed by washing cells three times with CSM and once with PBS. For cellular DNA 
staining, an iridium-containing intercalator (Fluidigm) was diluted to 250 nM in PBS 
containing 1.6% PFA, added to the cells at 4°C, and incubated overnight. Before 
measurement, the intercalator solution was removed and cells were washed with CSM, 
PBS, and doubly distilled H2O. After the last wash step, cells were resuspended in MilliQ 
H2O to 1 million cells/mL and filtered through a 40-µm strainer. 
Mass cytometry data processing 
EQ Four Element Calibration Beads (Fluidigm) were added to the cell suspension in a 
1:10 ratio (v/v). Samples were measured on a CyTOF1 system (DVS Sciences). The 
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manufacturer’s standard operation procedures were used for acquisition at a cell rate of 
∼300 cells per second as described previously (59). After the acquisition, all FCS files 
from the same barcoded sample were concatenated using the Cytobank concatenation 
tool. Data were then normalized and bead events were removed (60). Cell doublet 
removal and de-barcoding of cells into their corresponding wells was done using a 
doublet-free filtering scheme and single-cell deconvolution algorithm (61). Subsequently, 
data were processed using Cytobank (http://www.cytobank.org/). Additional gating on the 
DNA channels (191Ir and 193Ir) was used to remove remaining doublets, debris, and 
contaminating particles. Final events of interest were exported as .csv files. 
 
In-depth analysis of breast cancer EMT cell-state space and drug-inhibitor manifold 
from a single mass cytometry run 
CyTOF measurements of cells undergoing unperturbed and perturbed EMT were 
generated and processed as described above. Data were then pooled from all 
experimental conditions, taking an equal random subsample from each condition to 
generate the cell-state embedding. Cell state definitions and relationships were modeled 
with PHATE. Subsequently, all cells from all experimental conditions were assigned a 
cell subtype using a nearest-neighbor approach. 
Next, the cell subtype composition of each inhibition condition (i.e., relative 
frequencies of each cell subtype that sum to one for each sample) was determined. Using 
this cell subtype frequency-based representation of inhibition conditions, EMD was 
computed pairwise between single-cell samples. Euclidean distances between cluster 
centroids in the PHATE space (which approximate diffusion-based potential distances 
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derived from the expression data native dimensions (37)) were used as a measure of 
intrinsic dissimilarity between cell subtypes for the EMD ground-distance matrix. EMD 
in this case represented the minimum “effort” required to transform one inhibition 
condition to another (conceptually equivalent to the total “effort” needed to move cells 
from relatively “overweight” parts of the branched, continuous, EMT cell-state manifold 
to relatively “underweight” parts). The EMD between every pair of inhibition conditions 
was computed to construct a network of drug inhibition conditions, represented as an 
EMD-based distance matrix. The resulting distance matrix was embedded using the 
diffusion map approach (as implemented in the ‘destiny’ Bioconductor R package (36)) 
and partitioned using hierarchical clustering (applied to the untransformed distance 
matrix) to highlight inhibitors with significant effects on EMT or similar effects to one 
another. 
 
Integrating batch-effect correction to compare 300 EMT inhibition and control 
conditions measured in five experimental runs 
CyTOF measurements of cells undergoing unperturbed and perturbed EMT were 
generated and processed as described in the above sections. Markers shared across all 
batches (n = 31) were used for downstream analyses. Data were pooled from all 
experimental conditions on a per-batch basis. Expression values were then linearly scaled 
for each gene to ensure all values were positive and in the same range across batches. 
After this initial normalization, an equal random subsample of cells from each batch 
(20,000 x 5) was used as the input for canonical correlation analysis (CCA) (62). CCA 
mapped expression data from each batch into an aligned, 8-dimensional space shared by 
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all batches. The cell state manifold and cell subtype definitions were modeled by 
applying the PHATE dimensionality reduction and clustering method to the eight 
dimensions of the CCA-aligned space as input. 
All cells from all experimental conditions were assigned a cell subtype using a 
nearest-neighbor approach. Next, the cell subtype composition of each inhibition 
condition (i.e., relative frequencies of each cell subtype that sum to one for each sample) 
was determined. Using this cell subtype-based representation of inhibition conditions, 
EMD was computed pairwise between single-cell samples. The ground distance (i.e. 
intrinsic dissimilarity) between cell subtypes was defined as the Euclidean distance 
between their respective centroids in the three-dimensional PHATE space. The resulting 
specimen-to-specimen distance matrix was embedded using the ‘destiny’ Bioconductor R 
package (36) and partitioned using hierarchical clustering (applied to the untransformed 
distance matrix) to identify 13 clusters of inhibitors with similar effects on EMT. 
 
Intrinsic dimensionality analysis of the EMT perturbation state space 
The bias-corrected maximum likelihood estimator approach was used to assess the 
intrinsic dimensionality of the EMT perturbation state space (63). The specimen-to-
specimen distance matrix for the 300 samples was computed as described above and the 
intrinsic dimensionality of this embedding was estimated using the ‘ider’ R package (64). 
Intrinsic dimensionality was estimated over a range of values for knn parameter F from 1 
through 100. The final value of intrinsic dimensionality was determined by examining the 
stable estimated value across a range of sufficiently large values for F	(defined as >30). 
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Imputing the effects of inhibitions based on a small measured dictionary 
A previously published sampling technique for identifying landmark points of an 
embedding was applied to assess whether the network geometry of all 300 inhibition and 
control conditions could be captured using a smaller subset of conditions (65). The 
technique, called “incompletely pivoted QR-based (ICPQR) dimensionality reduction,” 
learns a concise embedding of a large collection of datapoints by identifying a subset of 
“landmark points” that collectively capture the geometry of the full collection of samples. 
The fundamental concept is that these H	landmark points comprise an H-dimensional 
subspace and that all other existing and new points can be mapped in relation to these. 
ICPQR identifies the concise “landmark point” dictionary based on known pairwise 
distances between samples (e.g., our EMD-based distance matrix of sample-to-sample 
distances). The ICPQR procedure was applied as follows: first, the PhEMD distance 
matrix containing pairwise distances between our 300 experimental conditions was 
converted to an affinity matrix using a Gaussian kernel (I = 2) and Markov-normalized 
to obtain probabilities. The (ICPQR) dimensionality reduction technique was then 
applied to this affinity matrix, using a K distortion parameter of 0.01, to identify 34 
landmark points. To assess whether the 34 landmark points adequately captured the 
geometry of the full collection of 300 samples, the landmark points identified were then 
used to impute the geometric coordinates of the remaining (non-landmark) points using 
the out-of-sample extension technique associated with ICPQR (65). The result was a 34-
dimensional embedding of all 300 samples. We computed a 300x300 distance matrix 
based on the pairwise Euclidean distances between samples in this 34-dimensional space 
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and then embedded it using the ‘destiny’ Bioconductor R package (36). 
 
Incorporating drug-target binding specificity data to extend the PhEMD embedding 
and predict the effects of unmeasured inhibitors on TGFβ-induced EMT 
We hypothesized that the influence of additional inhibitors on TGFβ-induced EMT could 
be predicted based on knowledge of inhibitor–inhibitor similarity from another data 
source. To test this, we obtained drug-target specificity data from a previously published 
experiment for a set of 39 inhibitors that overlapped between our experiment and theirs 
(66). Saracatinib, ibrutinib, and dasatinib were selected as three nonspecific Src inhibitors 
whose drug-target specificity data were known and whose effects on EMT we wanted to 
predict. Next, a PhEMD embedding was generated based on our CyTOF experimental 
results (not including the three selected inhibitors). To predict the effects of the three 
inhibitors on EMT relatively to other inhibitors in our experiment, we performed 
Nystrom extension on the diffusion map embedding. All 39 inhibitors that were found to 
have an effect on EMT in our experiment and that had known drug-target specificity 
profiles were included in the Nystrom extension. Pairwise distances between each 
“extended” point and each existing point in the original diffusion map were required for 
Nystrom extension. These distances were based on the similarity of drug-target 
specificity profiles between the two inhibitors, defined as (1 − MNO7:P	O787QRS7TU)VW ∗ 4 
for all pairs of inhibitors with known drug-target specificity profiles. The remaining 
pairwise distances were imputed based on known PhEMD-based inhibitor–inhibitor 
dissimilarity and known pairwise drug target specificity-based dissimilarity using the 
MAGIC imputation algorithm (67). 
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A global shift in embedding coordinates between the original diffusion map 
(based on PhEMD distances) and the Nystrom extension points (based on normalized 
cosine similarity using drug-target specificity data) was observed. This was likely due to 
a difference in scale between PhEMD-based distances and cosine similarity-based 
distances. Nonetheless, we were able to use the Nystrom extension points alone to predict 
the effect of the three selected inhibitors on EMT. First, we visualized the Nystrom 
extension embedding to show the predicted relation of the three inhibitors to other 
inhibitors with known (measured) effects on EMT. Next, we used partial least squares 
regression (‘pls’ R package (68)) to predict the cell subtype relative frequencies that 
would result from applying the inhibitors to breast cancer cells undergoing TGFβ1-
induced EMT. Nystrom extension embedding coordinates were used as the input 
variables for the regression model. To validate our findings, we measured the three 
selected inhibitors directly using CyTOF and included them along with the rest of the 
inhibitors in the PhEMD analysis pipeline. We compared the actual to the predicted cell 
subtype relative frequencies and the actual to the predicted embedding coordinates 
relative to other similar, “nearby” inhibitors. To assess prediction accuracy, we compared 
our prediction error to the prediction error of the null hypothesis modeled by first 
randomizing the PhEMD-based and drug target specificity-based distance matrices and 
then generating a predictive model in the same way as in the alternative model. 
Prediction error was defined as the EMD between the predicted and actual (measured) 
cell subtype relative frequency distributions. The null hypothesis was modeled as a 
distribution of EMDs generated by randomizing the PhEMD-based and drug target 
specificity-based distance matrices 1,000 times and subsequently imputing cell subtype 
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frequencies. P-values were computed by performing a permutation test (n=1,000) 
comparing our prediction error to that of the empirical null distribution and applying a 
one-sided significance test at a significance level of 0.05. 
To more comprehensively assess PhEMD as a predictive tool, leave-one-out cross 
validation was performed on the 39 inhibitors with known (measured) cell subtype 
relative frequencies and drug-target specificity data. For each inhibitor, we constructed a 
PhEMD embedding based on known measurements of the 39 others and performed 
Nystrom extension to impute the relationship between the inhibitor and the measured 
ones. We then constructed a partial least squares regression model using the same input 
variables as above to predict the cell subtype relative frequencies of the inhibitor. 
Prediction error was defined the same as above (i.e. EMD between predicted and actual 
cell subtype relative frequency distributions). The null model was also defined in the 
same way as above by randomizing the PhEMD and distance matrices 100 times for the 
prediction of each inhibitor. To determine whether our alternative model was effective, 
we assessed whether the prediction errors in the alternative model (n=39) were lower 
than the EMDs in the null model (n=3,900) using a one-sided Mann-Whitney U-test. 
 
Predicting drug-target binding specificities based on PhEMD results from EMT 
perturbation experiment 
We hypothesized that if the PhEMD embedding were meaningful, it would have 
predictive power. In order to test this, we used the PhEMD embedding of inhibitors to 
predict the inhibitors’ drug-target binding specificities. The drug-target binding 
specificity data were obtained from a previously published study that used a chemical 
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proteomic approach to identify the protein targets of many clinical kinase inhibitors (66). 
We chose to predict the profiles of 39 inhibitors that were present in both the drug-target 
binding specificity experiment and ours, and that had at least 1 protein target identified by 
the binding specificity experiment. Next, we computed a 39-by-39 knn kernel (k=3) using 
the PhEMD inhibitor–inhibitor distances and then row-normalized the resulting matrix to 
1 to turn it into a Markov operator. We then performed a leave-one-out cross validation, 
in which we set one of the inhibitor target values (i.e., drug-target binding specificity 
profiles) in the Klaeger et al. data to be unknown. Note that a drug-target binding 
specificity profile was represented as a vector of length 270, which represented the 
binding specificity between the drug and each of 270 potential protein targets. We 
predicted the drug-target binding specificity values using the MAGIC imputation 
method (67) with the PhEMD Markov operator as input and a diffusion parameter T of 2. 
We computed leave-one-out predictions for each of the 39 inhibitors. To quantify the 
performance of our predictive model, we computed Pearson correlation between the 
original ground-truth (experimentally measured) target values and the predicted values. 
To determine the accuracy of our predictions, we compared our results to a null model, in 
which we randomized the PhEMD matrix 1,000 times and each time ran the prediction 
using this randomized matrix. Prediction accuracy (Pearson correlations) of our 
alternative model (n=39 predictions, one per inhibitor) was compared to that of the null 




Generation and analysis of dataset with known ground-truth branching structure 
To evaluate the accuracy of the PhEMD analytical approach, high-dimensional single-cell 
data (‘Synthetic Dataset B’) were generated using Splatter, a previously published tool 
designed to simulate single-cell expression data (69). The basic tree structure represented 
in Figure 4A was generating using the following Splatter parameters: nGenes=100, 
de.prob=0.5, path.from=c(0,0,0,3,3,5,5,7,7,7). Each single-cell sample consisted of 2000 
cells sampled from this cell-state manifold at varying degrees of cellular density spread 
across the cell-state space. For Samples A-I, cellular density was concentrated in cell 
subtypes C-1 through C-9 (constituting the main axis), with 55% of Sample A consisting 
of C-1 and C-2 cells and 55% of Sample I consisting of C-8 and C-9 cells. Samples B-H 
consisted of progressively fewer cells in the starting cell states (i.e., C-1 and C-2) and 
progressively more cells in the terminal cell states (i.e., C-8 and C-9). Samples X, Y, and 
Z were enriched for cells in C-10, C-13, and C-14 respectively. Samples J-M were 
comprised predominantly of C-11 cells and Samples N-Q were comprised predominantly 
of C-12 cells at increasing degrees of cell-type enrichment. 
We applied PhEMD to the library-size normalized Splatter data as outlined in 
Figure 2. First, the tree structure was modeled by PHATE based on cells aggregated from 
all biological specimens. Then, the relative frequency of cells across different cell 
subtypes was computed for each specimen. EMD was computed pairwise for all cells 
using PHATE distances as a measure of ground-distance between cell subtypes. A final 
diffusion map embedding of biospecimens was generated using the ‘destiny’ 
Bioconductor R package. 
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Analysis of melanoma single-cell RNA-sequencing dataset 
Data from a prior single-cell RNA-sequencing experiment were downloaded from the 
NCBI Gene Expression Omnibus website, accession number GSE72056 (12). These data 
contained read-count expression values that were log TPM-normalized values. 2 of the 19 
samples were excluded from analysis due to low cell yield of immune cells. Initial feature 
selection was performed by selecting 44 features found in the initial publication 
characterization of this dataset to distinguish between key cell types (12). The PHATE 
model of the cell-state space was constructed using default parameters to identify ten cell 
subtypes. The remaining PhEMD analysis pipeline was completed as described in ‘In-
depth analysis of breast cancer EMT cell-state space and drug-inhibitor manifold from a 
single mass cytometry run’; a final embedding of biopsy samples was generated using the 
‘destiny’ Bioconductor R package and partitioned using hierarchical clustering. 
 
Analysis of clear cell renal cell carcinoma dataset 
CyTOF data from a recent publication characterizing the immune landscape of clear cell 
renal cell carcinoma were downloaded from 
https://premium.cytobank.org/cytobank/projects/875 (13). Cell data were filtered and 
normalized using the method described in Methods section titled ‘Mass cytometry data 
processing’. The PHATE model of the cell-state space was constructed with a diffusion 
parameter t = 40 to identify ten cell subtypes. The remaining PhEMD analysis pipeline 
was completed as described in ‘In-depth analysis of breast cancer EMT cell-state space 




Statistical tests were performed as detailed in the above subsections. Differences in group 
medians were assessed using a Mann-Whitney U-test. Benchmarking of prediction 
accuracy (point estimate) against a null distribution was performed using a permutation 
(i.e., randomization) test. All statistical comparisons were performed at a two-sided 
significance level of 0.05 unless otherwise stated. 
 
Data availability 
The mass cytometry data that support the findings of this study are available at 
https://community.cytobank.org/cytobank/projects/1296. Any additional data supporting 
the findings of this study are available upon request. 
 
Code availability 
PhEMD (“Phenotypic Earth Mover’s Distance”) takes as input a list of H matrices 
representing H	single-cell specimens. An R implementation of PhEMD is publically 
available as a Bioconductor R package (package name: ‘phemd’) and can alternatively be 
downloaded from https://github.com/KrishnaswamyLab/phemd. Note that the cell-state 
space for all analyses presented in this manuscript was modeled using the PHATE 
method. However, alternative approaches are viable, and we have provided support for 
PHATE (37), Monocle2 (33), and Louvain community detection (as implemented in the 
Seurat software package (62)) for this purpose in the R package. 
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laboratory of Prof. Bernd Bodenmiller. Data quality assurance of these data was 
performed jointly by the author of this thesis (WSC) and NZ. WSC obtained the data for 
all other single-cell datasets as described above, wrote the software implementation of 




Overview of PhEMD 
PhEMD is a method for embedding a “manifold of manifolds,” i.e., sets of datapoints in 
which each datapoint itself represents a collection of points that comprise a manifold. In 
the setting of analyzing single-cell data, each datapoint in the “manifold of manifolds” 
represents an experimental condition (i.e., single-cell specimen), which is itself 
comprised of a heterogeneous mixture of cells that span a cell-state manifold. PhEMD 
first embeds each biospecimen as a manifold and then derives a pairwise distance 
between the manifolds. Deriving an “higher-level” embedding then involves using these 
pairwise specimen-to-specimen distances to find a coordinate system (i.e., axes of 
variability) such that each point represents a specimen, and the distance between the 
points represents the dissimilarity between specimens. PhEMD derives such an 
embedding using the following general steps (Figure 2): 
1. Compute a distance between each pair of datasets (i.e., experimental conditions) 
as follows: 
a) Embed points within each dataset using PHATE (37). 
b) Cluster datapoints using spectral clustering. 
c) Represent each dataset as a vector of relative cluster proportions. 
d) Compute the distance between two datasets using Earth Mover’s Distance 
(EMD). 
2. Take the distance matrix derived from the previous step and compute a diffusion 
map embedding of the data (34). 
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When specifically applied to single-cell data, PhEMD leverages PHATE and spectral 
clustering to define cell subtypes, EMD to compute pairwise distances between 
biospecimens (based on their cell subtype relative abundances), and the diffusion map 
approach to generate a final low-dimensional embedding of biospecimens. Pseudocode 
and additional details on the PhEMD algorithm can be found in Methods. 
 
Comparing specimens pairwise using Earth Mover’s Distance (EMD) 
A critical component of deriving the correct single-cell specimen embedding is 
computing accurate specimen-to-specimen distances. Two existing methods for doing so 
are cellAlign (43) and sc-UniFrac (44). However, both impose limiting assumptions or 
faced scalability issues that are addressed in our implementation of EMD. 
cellAlign was designed to compare two experimental conditions (i.e., two 
heterogeneous cell populations) by first modeling each condition as an unbranched 
trajectory of cells, then assigning a pseudotime value to each cell based on its ordinal 
position in the trajectory, and finally computing a distance between the two experimental 
conditions as the “cost” of aligning the two pseudotemporal trajectories. By nature of its 
implementation, cellAlign cannot be applied to cell populations sampled from branched 
cell-state trajectories, as it assumes cells with the same pseudotime value have identical 
gene expression profiles (an assumption violated in the setting of branched cell-state 
trajectories). Our implementation of EMD does not make such an assumption and is thus 
more flexible for analyzing datasets with branched cell-state trajectories. 
sc-UniFrac is a different method that was similarly designed to compare two 
single-cell experimental conditions but that faces scalability issues. Its memory 
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requirements exceed that of a standard laptop (2.5 GHz Intel Core i7 processor, 16 GB 
RAM) when attempting to compare experimental conditions containing collectively 
greater than 40,000 cells using default parameters. This prevents it from being useful for 
analyzing large multi-specimen datasets such as our drug-screen experiment spanning 
300 experimental conditions and over 1.7 million cells. In contrast to sc-UniFrac, which 
is unable to be run on a laptop to analyze a set of 40,000 cells from two or more 
experimental conditions, PhEMD can be successfully run on the same laptop to analyze a 
set of over 360,000 cells from 60 experimental conditions in under 10 minutes. In light of 
these memory-based limitations of sc-uniFrac, we compared the runtime of our 
implementation of EMD to sc-uniFrac using a smaller dataset consisting of 20 single-cell 
specimens each containing 500 cells sampled from a cell-state tree (“Synthetic Dataset 
A”). The cell-state tree was generated using the Splatter R package and was characterized 
by four branches sharing a single branch point. Our implementation of EMD correctly 
recovered the known cell-state space of the dataset (Figure 3A) and had faster empiric 
runtime than when analyzing datasets including more than 21,000 cells in total (Figure 
3B). 
 
Figure 3. a) PHATE embedding of the cell-state space of Synthetic Dataset A colored by cell-subtypes 
identified by PHATE. b) Runtime comparison between PHATE and sc-UniFrac applied to datasets of 
increasingly larger sample sizes. 
 
In sum, unlike cellAlign, which can only be applied to datasets in which all cells 
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across all specimens were mappable to a single unbranched trajectory (e.g., a simple 
differentiation process), our approach can be used to compare specimens comprised of 
cells sampled from an underlying cell-state manifold that is potentially branched. 
Compared to sc-UniFrac, our implementation of EMD is much more scalable, allowing 
for the efficient pairwise comparison of multiple specimens as is required to generate a 
final embedding containing many single-cell specimens.  
 
Evaluating accuracy of PhEMD in mapping multi-specimen, single-cell dataset with 
known ground-truth structure 
We first applied PhEMD to simulated single-cell data with known ground-truth structure 
to determine whether PhEMD could accurately model both the cellular heterogeneity 
within each specimen and the specimen-to-specimen heterogeneity based on cell subtype 
relative abundances. The simulated cells lay on a continuous branched trajectory, wherein 
progression along a branch represented concurrent changes in gene expression in select 
differentially expressed genes (69). The distribution of cell density across branches was 
varied between specimens to simulate a heterogeneous multi-specimen dataset. PhEMD 
correctly recovered the branched cell-state manifold structure using PHATE (Figure 4A-
B). The specimen-to-specimen EMD-based comparison and resulting PhEMD embedding 
were also found to be accurate (Figure 4C).  
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Figure 4. a) Ground-truth tree structure of the cell-state space of Synthetic Dataset B (see Methods for data 
parameters). b) PHATE embedding of the cell-state space of Synthetic Dataset B, colored by cell-subtypes 
identified by PHATE. Grey dotted line denotes major axis (comprised of cell subtypes C-1 through C-9) 
along which density is modulated for biospecimens A–I. c) Diffusion map embedding of biospecimens. 
Points colored black and labeled A–I represent samples that have density concentrated at various clusters 
along the trajectory from C-1 (“starting state”) and ending at C-9 (“terminal state”) highlighted in grey. The 
alphabetical ordering of samples from A–I correspond to increasing intra-sample relative proportions of 
starting state to terminal state points. Samples X and Y represent specimens with cells concentrated in 
clusters C-13 and C-14 respectively (i.e. highly similar cell subtypes), and Sample Z represents a specimen 
with cells concentrated in cluster C-11 (highly dissimilar to cell subtypes C-13 and C-14). d) Relative 
frequency histograms representing distribution of cells across different cell subtypes for selected samples 
forming a sub-trajectory in the biospecimen embedding. 
 
The accuracy of the final PhEMD biospecimen map was then assessed as follows. 
First, we examined the single-cell specimens in which a large number of cells were 
concentrated in a single branch. We found that specimens with cellular density 
concentrated in branches close to one another on the cell-state manifold (e.g. Samples X 
and Y) tended to map to regions close to one another on the biological-specimen 
manifold compared to specimens with cellular density concentrated in branches far from 
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one another on the cell-state manifold (e.g. Samples X and Z). Next, we examined 
Samples A–I: specimens in which cellular density was modulated so that Sample A had 
cells mostly in the arbitrary “starting” state of the manifold, Sample I had cells mostly in 
an arbitrary “terminal” state, and Specimens B through H had progressively fewer cells in 
the “starting” state and more cells in the “terminal” state. We found that in the final 
biospecimen embedding, Samples A–I appropriately formed a trajectory and were 
ordered based on their intra-specimen relative proportions of “starting state” to “terminal 
state” cells. Finally, we examined Samples J-Q: specimens in which point density was 
concentrated in intermediate branches diverging from the main trajectory of the cell-state 
manifold (i.e., cell subtypes C-11 and C-12). We found that PhEMD correctly mapped 
these specimens to distinct branches in the final single-cell specimen embedding and 
correctly ordered them in terms of increasing enrichment of the C-11 and C-12 cell types. 
Overall, this demonstrated that our approach accurately inferred both the cell-type 
frequencies in each specimen and the similarity between cell subtypes.  
 
Assessing the differing effects of selected drug perturbations on EMT in breast 
cancer 
To study key regulators of epithelial-to-mesenchymal transition (EMT) in breast cancer, 
we performed a drug screen consisting of 300 inhibition and control conditions, 
collectively inhibiting over 100 unique protein targets in murine breast cancer cells 
undergoing TGFβ1-induced EMT (Figure 5, Table S1). These specimens collectively 
contained over 1.7 million cells measured in a total of five mass cytometry runs. Time-of-
flight mass cytometry (CyTOF) was used on day 5 of cell culture to measure the 
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concurrent expression of 31 protein markers in each cell (Table S2), and PhEMD was 
used to model both the cell-state transition process and the perturbation-effect manifold. 
Batch correction was performed using canonical correlation analysis (CCA) prior to 
modeling the cell-state and single-cell specimen embeddings in order to analyze all 
experimental conditions across all plates simultaneously. 
Figure 5. Experimental design for measuring perturbation effects of small molecule inhibitors on TGFβ1-
induced EMT. 
 
Batch effect correction in multi-run EMT experiment 
Batch effect is a well-known problem when comparing data from multiple single-cell 
RNA-sequencing (62, 70) or CyTOF (71, 72) experiments. Because of this, single-cell 
specimens are ideally processed and measured in a single batch. However, comparing 
specimens across experimental runs is still of great interest. In some cases, the sheer 
number of specimens makes simultaneous processing impossible. In other cases, the 
experimental design (e.g. time-series analysis) precludes sample processing on the same 
plate or gene profiling of all specimens simultaneously. In order to enable these sorts of 
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experiments, a number of methods have been recently published that correct for batch 
effect. We chose canonical correlation analysis (CCA), a new feature of the popular 
Seurat package, as our batch correction tool and demonstrated that PhEMD can leverage 
existing batch correction methods to compare hundreds of specimens from five 
experimental runs. 
To assess the presence of batch effect in our multi-plate experiment prior to batch 
effect normalization, we performed t-SNE dimensionality reduction on an equal, random 
subsample of cells from each batch (Figure 6). Since each batch used the same Py2T 
breast cancer cell line and contained a relatively similar mix of inhibition and control 
conditions, batches were expected to have more shared than non-shared cell subtypes. If 
true, this phenomenon would appear as extensive inter-plate mixing in most regions of 
the t-SNE cell state space. This is because most sources of variation in the data were 
expected to be attributable not to the plate on which specimens were cultured or CyTOF 
run in which specimens were measured, but instead to specimen-specific biology. 
Visualizing the t-SNE embedding and coloring cells by their original batch (Figure 6A), 
we noticed poor inter-plate mixing. This indicated that batch effect was present in the 
unnormalized data. 
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Figure 6. t-SNE embedding of cells from multiple CyTOF runs based on gene expression data a) pre- and 
b) post-CCA batch correction, with individual cells colored by experimental batch. 
 
We then applied CCA to the expression measurements and ran t-SNE on the 
batch-corrected data (Figure 6B). Reassuringly, we noticed that there was strong inter-
plate mixing when coloring cells in the t-SNE embedding by their original plate. This 
suggests that CCA effectively corrected for the technical sources of variation that 
appeared to be dominating the initial t-SNE embedding based on un-normalized 
expression data (Figure 6A). To assess whether batch effect correction not only removed 
technical sources of variation but also performed accurate data alignment, we examined 
the control conditions present on each plate. Two sets of identical control conditions were 
included on each plate: one set consisted of Py2T epithelial cells cultured with neither 
TGF-b1 nor drug inhibitor (“untreated controls”), and the other set consisted of Py2T 
cells stimulated with TGF-b1 and given no drug inhibitor (“uninhibited controls”). In our 
final clustering of specimens, we found that all of the untreated controls from all 5 plates 
clustered together and consisted almost entirely of the same epithelial cell population. 
Similarly, all of the uninhibited controls from all 5 plates clustered together and consisted 
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predominantly of late-transitional and mesenchymal cells. Moreover, inhibitors targeting 
the same molecular target tended to group together, irrespective of batch (e.g. Clusters D, 
E, F). These findings suggest that CCA accurately aligned the expression data.  
Cell-subtype definition via manifold clustering  
By design, all cells undergoing EMT were derived from the same homogeneous epithelial 
cell population. Thus, a continuous manifold with potentially branched structure (as 
modeled by PHATE) was ideal to model the cell-state space. Applied to the batch-
corrected expression data, and PHATE identified nine cell subtypes across all 
unperturbed and perturbed EMT conditions (Figure 7A-B).  
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Figure 7. a) PHATE embedding of cells from all 300 experimental conditions, colored by cell subtype. b) 
Heatmap representing log2 protein expression levels for each cell subpopulation representing its respective 
cell subtype. c) Diffusion map embedding of control and drug-inhibited conditions, colored by clusters 
determined by hierarchical clustering. d) Individual inhibitors assigned to each inhibitor group. Histograms 
represent bin-wise mean of relative frequency of each cell subtype for all inhibitors in a given group. The 
full list of inhibitors in each group can be found in Table S3.	
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C-1 was characterized by the following expression pattern: E-cadherin(hi) b-
catenin(hi) CD24(hi) vimentin(lo) CD44(lo). C-5 and C-6 had roughly the opposite expression 
profile with respect to the markers described above (Figure 7B). E-cadherin is the 
hallmark cell adhesion marker of epithelial cells (73), and vimentin and CD44 are known 
mesenchymal markers involved in cell migration (73–76). Moreover, recent studies found 
high CD44:CD24 expression to be indicative of breast cancer cell invasiveness and an as 
an EMT endpoint, suggestive of mesenchymal properties (77–79). C-3 was characterized 
by low-intermediate expression of both E-cadherin and vimentin, and C-4 was 
characterized by cells with intermediate levels of E-cadherin and vimentin and increased 
expression of p-MEK1/2, p-ERK1/2, p-p38-MAPK, p-GSK-3, and p-NFkB-p65. These 
subtypes were consistent with the “hybrid” cancer cells that co-express epithelial and 
mesenchymal markers (E+/M+) and simultaneously demonstrate both epithelial and 
mesenchymal properties (80–82). Altogether, the subtypes identified by PHATE are 
consistent with known epithelial, mesenchymal, and “hybrid” EMT cell phenotypes, and 
the trajectory defined by subtypes C-1 through C-6 in our model represent the epithelial-
to-mesenchymal transition process that one would expect to recover in our dataset. 
In addition to modeling the main EMT trajectory, the PHATE cell-state 
embedding identified additional cell subtypes mapped to regions of the cell-state 
manifold off of the main EMT axis. C-7 and C-8 were mapped close to the C-6 
mesenchymal subtype. C-7 was characterized by high expression of vimentin, CD44, 
cyclin B1, and pRb, and C-8 was characterized by high expression of vimentin, CD44, 
and phospho-S6. C-9 demonstrated high E-cadherin and cleaved caspase-3 expression 
and was consistent with an epithelial subpopulation undergoing apoptosis. By analyzing 
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our single-cell data with PHATE, which applied no prior assumptions on the intrinsic 
geometry of the cell-state embedding, we were able to uncover a more complex, 
continuous model of EMT than has been previously reported.  
Constructing and clustering the EMD-based drug-inhibitor manifold 
After modeling the EMT cell-state space with PHATE, PhEMD mapped the experimental 
variable (i.e., multicellular biospecimen) state space as a low-dimensional embedding 
(Figure 7C). Hierarchical clustering revealed clusters of inhibitors with similar net effects 
on EMT. Moreover, “uninhibited” controls (TGF-b1 applied in absence of any inhibitor) 
and “untreated” controls (neither TGF-b1 nor inhibitor applied) were included to 
distinguish inhibitors with notable effects on EMT. 
The final embedding of drug inhibitors highlighted the variable extent of EMT 
that had occurred in the different inhibition conditions (Figure 7C-D). This diffusion map 
embedding was low-dimensional with an intrinsic dimensionality of 2.4 (Figure 8), 




Figure 8. Intrinsic dimension of the PhEMD embedding comprised of 300-sample multi-batch EMT 
inhibition and control conditions, computed using the maximum likelihood estimation (MLE) approach 
over a range of “k” (k-nearest-neighbors parameter) values. 
 
Fourteen inhibitor clusters (Clusters A-N) were identified (Table S3). Cluster A included 
the untreated controls and the TGFβ1-receptor inhibitor condition, each of which 
consisted almost entirely of epithelial cells (C-1). These were experimental conditions in 
which EMT was effectively not induced. On the other hand, Cluster I included all 
uninhibited control conditions and inhibitors ineffective at modulating EMT; inhibitors in 
this cluster were found to have mostly mesenchymal (C-6) cells. Clusters B through H 
included inhibitors that had generally decreasing strength with respect to halting EMT 
(Figure 7C-D). The inhibitors in Clusters J and K formed a prominent trajectory off the 
main EMT-extent trajectory in the inhibitor embedding (Figure 7C). Clusters J and K 
were enriched in cell subtype C-8, with Cluster K inhibitors inducing cell populations 
that were almost entirely comprised of C-8 cells. 
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All of the Cluster K inhibitors targeted PI3K, Akt, or mTOR protein kinases – 
three members of a well-characterized pathway. Compared to the predominant 
mesenchymal subtype observed in the uninhibited controls (C-6), C-8 was comprised of 
cells with similarly high expression of vimentin and CD44 and markedly higher 
expression of phospho-S6 (Figure 7). This expression profile was consistent with an 
alternative-mesenchymal EMT subtype. Examining the cell yield of these inhibitors 
compared to the respective uninhibited control conditions in their respective batches, we 
found that the cell yield of the Cluster K inhibitors was on average 60% lower than the 
TGFβ1-only controls (Table S4). Based on these findings and a prior report that high 
expression of phospho-S6 was associated with resistance to PI3K inhibitors (83), the C-8 
subtype is likely a mesenchymal cell population relatively resistant to inhibition of the 
PI3K-Akt-mTOR axis. 
In general, small molecule inhibitors that had the same molecular target tended to 
cluster together, consistent with the intuitive notion that drugs with similar mechanisms 
of action likely have similar net effects on a given cell population (e.g. Cluster C, Cluster 
G). However, several inhibitors with the same reported primary target generated different 
resulting single-cell profiles and were clustered into different inhibitor clusters. This 
phenomenon may be due to differences in inhibitor potency and differences in off-target 
effects. 
 
Analyzing EMT perturbations measured in a single CyTOF run 
An analysis of a subset of 60 inhibition and control conditions measured in the same 
mass cytometry run (and hence not requiring batch normalization) was performed to 
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assess whether applying PhEMD to batch-normalized and single-batch expression data 
would yield consistent results. Three replicates involving independent cell culture 
experiments measured in distinct mass cytometry runs were analyzed to demonstrate 
reproducibility of results. 
Cell subtype definition via manifold clustering  
Our model of the cell-state space identified eight unique cell subtypes across all 
unperturbed and perturbed EMT specimens (Figure 9A-B). These included the starting 
epithelial subtype (C-1), main mesenchymal subtype (C-5), and transitional subtypes on 
the major EMT-axis (C-2 through C-4). C-1 was characterized by the following 
expression pattern: E-cadherin(hi) β-catenin(hi) CD24(hi) vimentin(lo) CD44(lo). C-4 and C-5 
had roughly the opposite expression profile with respect to the markers described above 
(Figure 9). C-6 through C-8 had expression profiles consistent with C-7 through C-9 in 
our multi-batch experiment (Figure 7B, Figure 9B). Altogether, the cell subtypes 
recovered in the single-batch and batch-normalized experiments were consistent with one 
another and with known EMT cell subtypes. 
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Figure 9. a) PHATE embedding of cells from all conditions of a single CyTOF run representing perturbed 
EMT cell state landscape, colored by cell subtype determined using spectral clustering. b) Heatmap of 
mean log2 protein expression levels for each subpopulation of cells representing a distinct cell subtype. c) 
Embedding of drug inhibitors, colored by clusters assigned by hierarchical clustering. d) Individual 
inhibitors assigned to each inhibitor group. Histograms represent bin-wise mean of relative frequency of 
each cell subtype for all inhibitors in a given group. The full list of inhibitors in each group can be found in 
Table S5. 
 
Note that in order to construct the cell-state manifold more efficiently, it was 
beneficial to generate the reference cell-state embedding on a subsample of all cells 
across all single-cell samples (and then to map unembedded cells to cell subtypes using a 
nearest-neighbor approach). For the analysis of our EMT dataset, we chose to subsample 
200 cells from each experimental condition. To assess whether this subsampling 
procedure had adverse effects on recovering accurate sample-to-sample distances, we 
first performed such a process on Synthetic Dataset A. We found that the sample-to-
sample distances were accurate (Pearson ρ > 99% between computed and ground-truth 
distances) when subsampling 200 cells from each sample, even when the 200 cells 
comprised as little as 1% of all cells in each sample. We then assessed whether the 
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subsampling procedure introduced variability into the sample-to-sample distances 
computed on our EMT dataset by comparing the correlation of results from 20 different 
random subsamples applied to the same EMT dataset. We found that the correlation 
between sample-to-sample distances across any two runs was greater than 98%. 
Altogether, these results demonstrated that 200 cells were an adequate subsampling size 
to yield stable results and that PhEMD was robust to different cell subsamplings.  
Constructing and clustering the EMD-based drug-inhibitor manifold 
After modeling the EMT cell-state space with PHATE, we used PhEMD to map the 
experimental variable (i.e., single-cell specimen) state space as a low-dimensional 
embedding. Specifically, EMD was computed pairwise between specimens based on cell 
subpopulational differences among samples, and these specimen-to-specimen distances 
(i.e., measures of dissimilarity) were used to generate a final low-dimensional diffusion 
map in which specimens mapped closer to one another represented samples with more 
similar cell subtype relative abundances (Figure 9C). The embedding of drug inhibitors 
constructed as described above was then partitioned by applying hierarchical clustering to 
the network of inhibitors. Note that the hierarchical clustering was performed on the 
EMD-based sample-to-sample distance matrix prior to applying diffusion map 
dimensionality reduction. Hierarchical clustering revealed clusters of inhibitors with 
similar net effects on EMT; inhibitors assigned to the same cluster were assumed to have 
similar effects on EMT. Moreover, by including “uninhibited” controls (samples in which 
TGF-b1 was applied to induce EMT in absence of any inhibitor) and “untreated” controls 
(samples in which neither TGF-b1 nor inhibitor was applied and no EMT was induced) in 
our experiment, we were able to identify inhibitors with notable effects on EMT. Those 
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inhibition conditions that clustered with uninhibited controls likely had little to no effect 
on EMT, whereas those that clustered with untreated controls halted EMT strongly and 
likely at an early stage. 
The final embedding of drug inhibitors revealed a manifold structure that 
highlighted the variable extent of EMT that had occurred in the different inhibition 
conditions (Figure 9C-D). Partitioning the embedding into nine clusters (Clusters A-I, 
Table S5), we found that Cluster A included the untreated controls and the TGFβ1-
receptor inhibitor condition, each of which consisted almost entirely of epithelial cells. 
These were the experimental conditions in which EMT was actually or effectively not 
induced. On the other hand, Cluster H included all five uninhibited control conditions and 
inhibitors ineffective at modulating EMT; inhibitors in this cluster were found to have 
mostly mesenchymal cells. Clusters B through G included inhibitors that had generally 
decreasing strength with respect to halting EMT (Figure 9C-D). The EGFR and MEK1/2 
inhibitors in Clusters B and C strongly inhibited EMT, as indicated by a marked 
predominance of epithelial cells at time of CyTOF measurement. Cluster G mostly 
consisted of Aurora kinase inhibitors and was characterized by a mixture of epithelial, 
transitional, and mesenchymal cells with a relatively high proportion of C-4 cells 
(consistent with the E+/M+ “hybrid” EMT phenotype).  
The three inhibitors in Cluster I formed a small branch off the main EMT-extent 
trajectory in the inhibitor embedding (Figure 9C). These three inhibitors targeted PI3K 
and mTOR and each demonstrated a cell profile characterized by a relatively high 
proportion of C-6 cells. Examining these results alongside measurements of cell yield in 
each inhibition condition (Table S4), we attributed the relatively greater proportion of C-
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4 cells in the setting of Aurora kinase inhibition and of C-6 cells in the setting of 
PI3K/mTOR inhibition to preferential drug-induced death of other cell types. C-4 and C-
6 cells were not uniquely generated by these inhibition conditions, as they were observed 
in other samples including the uninhibited EMT control conditions (Figure 9C), but 
appeared to have increased cell viability relative to other EMT cell types, especially in 
the setting of targeted kinase inhibition (Table S4). Note that these findings were 
consistent with those of the multi-batch experiment performed on batch-normalized data. 
Altogether, consistent results were observed across all single-batch and multi-batch 
analyses with respect to the resulting cell-state and higher-level biospecimen embeddings, 
demonstrating PhEMD’s reproducibility and robustness to batch-normalized data (Figure 
7, Figure 9–10). 
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Figure 10. a) Cell subtype expression patterns and cell-state embeddings for three independent 
experimental replicates. b) PhEMD biospecimen embeddings and inhibitor clusters for three independent 
experimental replicates. The full list of inhibitors in each group can be found in Table S5. 
 
Imputing the effects of inhibitors based on a small measured dictionary 
In our model breast cancer system, we were able to use PhEMD to assess the effects of a 
large panel of inhibitors on TGFβ1-induced EMT. We found that these inhibitors could be 
grouped into clusters based on the similarity of their effects and embedded in low 
dimension (with an intrinsic dimensionality of 2.4) to highlight complex, non-linear 
relationships between samples. Visualizing this embedding of inhibition conditions in 3D, 
we found that samples were distributed with varying density along a branched, 
continuous manifold. For example, the embedding space containing Cluster H inhibitors 
was characterized by high point density, while the embedding space containing Cluster B 
points was more sparsely populated (Figure 7C). We also noted that clusters often 
contained multiple inhibitors that targeted the same protein kinases. These findings 
suggested that we may have been able to capture the geometry of the drug-inhibition state 
space without measuring every single inhibition condition. If true, this finding would 
have implications for potentially reducing the cost of conducting single-cell drug-screen 
experiments, as it would suggest that only a small fraction of all inhibitors may need to 
be experimentally tested using expensive single-cell profiling techniques to assess the 
efficacy of a drug. 
To test this hypothesis, we applied a previously published sampling technique to 
our PhEMD embedding (65). The sampling technique used incompletely pivoted QR 
decomposition to identify “landmark points” (inhibition or control conditions) that 
approximately spanned the subspace of the single-cell sample embedding. Using this 
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approach, we identified 34 landmark points that summarized our EMT perturbation state 
space (Figure 11A). The 34 landmark points included samples from all 14 of Clusters A-
N, suggesting they spanned all classes of experimental conditions in our experiment. To 
more fully assess whether the landmark points adequately captured the perturbation 
landscape of our full 300-sample experiment, we applied an accompanying out-of-sample 
extension technique to infer the embedding coordinates of all 300 samples relative to 
these 34 landmark points. The resulting embedding had a similar geometry to that of our 
original 300-sample PhEMD embedding, suggesting that the 34 landmark points were 
sufficient to capture the overall network structure of all 300 measured experimental 
conditions (Figure 7C, Figure 11B). Comparing the pairwise sample–sample distances of 
all 300 samples in the 34-dimensional landmark-point space to the experimentally 
computed EMD sample–sample distances, we found that there was strong correlation 
between these distances (ρ=0.92). These findings supported the notion that redundancies 
may exist in a drug screen experiment, and that one may not need to measure an 
exhaustive set of perturbation conditions in order to infer the effects of all perturbations. 
This highlights a potential opportunity for reducing the cost and improving the feasibility 
of future single-cell drug-screen experiments. Based on our findings, only a small 
fraction (11%) of all inhibitors may need to be experimentally measured using expensive 
single-cell profiling techniques to learn the full spectrum of perturbation effects. 
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Figure 11. a) Diffusion map embedding of 300-specimen EMT experiment, plotting only the 34 landmark 
points identified using a previously published diffusion map sampling technique (see Methods). Points are 
colored based on cluster assignments as determined based on original clustering of all 300 samples (see 
Figure 7C). b) Reconstructed diffusion map embedding, generated by starting with the 34 landmark points 
and using a previously published out-of-sample extension technique to infer the embedding coordinates of 
all 300 samples relative to these 34 landmark points (see Methods). 
 
Validating the PhEMD embedding using external information on similarities 
between small-molecule inhibitors 
We sought to validate our PhEMD drug-screen embedding by comparing the drug-drug 
similarities learned from our experiment (in the context of effects on EMT) to drug-drug 
similarities based on known drug-target binding specificities from a prior 
experiment (66). Since the prior experiment and ours measured an overlapping set of 
inhibitors, they could be conceptualized as two complementary “views” of the same 
shared inhibitors. We hypothesized that for the inhibitors shared between the two 
experiments, one view of the data might inform the other. Intuitively, this would support 
the notion that drugs with more similar protein targets action may tend to have more 
similar effects on EMT (and vice versa). Our approach to assessing this hypothesis was 
twofold: 1) We used a measure of inhibitor–inhibitor similarity, derived from the drug-
target specificity data, to extend our PhEMD embedding and predict the effects of 
unmeasured inhibitors on our model EMT system, and 2) We used our PhEMD 
embedding to predict the drug-target specificity of inhibitors shared between the two 
drug-screen experiments. 
Predicting the effects of three selected inhibitors on breast cancer EMT relatively to the 
effects of measured inhibitors based on known drug-target binding specificities 
For the first task, we sought to evaluate whether we could leverage known information on 
the mechanistic similarity between our inhibitors and additional inhibitors not measured 
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in our experiment to predict the effects of these additional inhibitors on EMT. We 
selected saracatinib, ibrutinib, and dasatinib as three nonspecific Src inhibitors whose 
effects on EMT we wanted to predict. First, we generated a PhEMD embedding based on 
our CyTOF experimental results (not including the three selected inhibitors). Then, we 
obtained drug-target specificity data from a recently published inhibitor-profiling 
experiment for inhibitors that overlapped between our experiment and the recently 
published one (including the 3 Src inhibitors of interest). We used the drug-target 
specificity data to compute pairwise cosine similarities between each of the 3 Src 
inhibitors and the samples in our initial PhEMD diffusion map embedding (that did not 
include the 3 inhibitors). These pairwise similarities were used to perform Nystrom 
extension—a method of extending a diffusion map embedding to include new points 
based on partial affinity to existing points (84–86). In this way, we were able to predict 
the effects of the three Src inhibitors on breast cancer EMT relatively to inhibitors with 
known, measured effects (Methods). 
To validate our extended embedding containing predicted Src inhibitor effects, we 
compared it to a “ground-truth” diffusion map embedding that used known (measured) 
CyTOF expression data for the 3 inhibitors and explicitly included the 3 inhibitors along 
with the rest in the initial embedding construction. Benchmarking our predictions against 
this ground-truth model, we found that our predictive model mapped the three inhibitors 
to the correct phenotypic space (Figure 12A-B). Specifically, saracatinib and ibrutinib 
were predicted to have an effect intermediate to those of specific MEK and EGFR 
inhibitors, and dasatinib was predicted to halt EMT less strongly than the other two Src 
inhibitors. These findings are consistent with ground-truth results based on direct CyTOF 
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profiling and PhEMD-modeling of the three inhibitors (Figure 12B; Methods). 
 
Figure 12. a) Nystrom extension embedding showing predicted effect of 3 selected inhibitors (dasatinib, 
ibrutinib, saracatinib) on EMT relatively to other measured inhibitors. b) PhEMD diffusion map embedding 
showing measured effects of 3 selected inhibitors on EMT. c) Histogram showing distribution of prediction 
error for null model (n=1000 independent permutations). Dotted red line represents prediction error for 
actual prediction (i.e., alternative model). P-values were computed using a one-sided permutation test. 
 
Imputing the single-cell phenotypes of three unmeasured inhibitors based on drug-target 
similarity to measured inhibitors 
We also hypothesized that we could use drug-target information to not only relate 
unmeasured inhibitors to measured ones but also impute their single-cell compositions. 
To test this, we used the Nystrom-extended PhEMD embedding as input into a partial 
least squares regression model. We used this model to impute the cell subtype relative 
frequencies for the three unmeasured (imputed) Src inhibitors (Methods). As validation, 
we compared the predicted cell subtype relative frequencies to ground-truth CyTOF 
results (i.e., actual single-cell measurements) for the three inhibitors. PhEMD accurately 
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predicted the cell subtype relative frequencies for the three inhibitors compared to the 
null model (P=0.01, P=0.01, P=0.03; Figure 12C).  
To assess more generally whether PhEMD could be integrated with 
complementary data to accurately predict perturbation effects, we performed leave-out-
out cross validation on all 39 inhibitors in our CyTOF experiment with known drug-target 
specificity data (Methods). We found that single-cell profile predictions leveraging our 
imputed PhEMD embedding were significantly more accurate than a null model 
(P=0.005). Altogether, these findings suggested that PhEMD offered information that 
could be integrated with additional data sources and data types to support not only 
comparison of biospecimens directly measured but also prediction of single-cell 
phenotypes for additional, unmeasured specimens. 
Predicting drug-target binding specificities based on PhEMD results from EMT 
perturbation experiment 
We found that knowledge of drug-target binding specificity could be used to predict 
inhibitor effects in our model EMT system. We then sought to assess whether the reverse 
was true – whether the learned relationships between inhibitors from our EMT 
perturbation experiment could be used to predict drug-target binding specificities. For 
this prediction task, we used the 39 inhibitors that were present in both the drug-target 
profiling experiment and ours, and that had at least 1 protein target identified by their 
experiment. We then computed leave-one-out predictions using the MAGIC imputation 
algorithm (67) and results from our EMT perturbation screen experiment to predict the 
drug-target binding specificities of each inhibitor. Prediction accuracy was defined as the 
correlation between predicted and measured drug-target binding specificities for a given 
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drug. Our predictive model that incorporated PhEMD results into the prediction was 
significantly more accurate than the null model (P=6.57x10-5; Figure 13). This suggested 
that while the two experiments measured two distinct sets of inhibitor features, the 
inhibitor–inhibitor relationships learned from both experiments were consistent.  
 
Figure 13. a) Probability density functions representing distribution of Pearson correlations between 
predicted and known drug-target binding specificity profiles. The null (n=39,000 predictions from 1,000 
independent permutations) vs. alternative (n=39 predictions) models demonstrated median correlation-
based accuracy of 0.02 vs. 0.25, P=8.2*10-6. Statistical testing was performed using a one-sided Mann-
Whitney U-test. b) Pearson correlation-based prediction accuracy of null (n=1,000 permutations per 
inhibitor) vs. alternative (one prediction per inhibitor) models for predicting the drug-target binding 
specificity of each inhibitor. Given multiple null-model predictions for each inhibitor, the y-axis represents 
mean prediction accuracy of all predictions for a given inhibitor. See Methods for detailed properties of the 
null and alternative models. 
 
 
PhEMD highlights manifold structure of tumor specimens measured using CyTOF 
and single-cell RNA-sequencing 
To demonstrate an additional application of the PhEMD analytical approach, we 
used PhEMD to characterize the specimen-to-specimen heterogeneity in immune cell 
profiles of multiple tumor specimens. We first applied PhEMD to a single-cell RNA-
sequencing dataset consisting of the “healthy” (non-malignant) cells of 17 melanoma 
biopsies. The cell-state embedding identified a total of 10 cell subtypes with gene 
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expression profiles consistent with previously reported subpopulations of B cells, T cells, 
endothelial cells, epithelial cells, NK cells, and monocytes (Figure 14A-B) (12). Cell 
subtypes C-1 and C-2 both represented CD8+ T cells. C-1 demonstrated high expression 
of TIGIT, CTLA4, and LAG3 and was consistent with a T-cell exhaustion profile (87). C-
3 was comprised of CD4+ T cells. C-6 and C-7 represented CD19+ BLK+ B cells with 
differences in the expression of SELL and CCR7. C-8 represented CD14+ monocytes 
(88), C-9 represented PECAM1+ vWF+ CDH5+ endothelial cells, and C-10 represented 
epithelial cells with high collagen expression. 
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Figure 14. PhEMD applied to scRNA-sequencing data of 17 melanoma samples (non-tumor cells only) 
highlights heterogeneous immune response amongst different patients. a) PHATE cell state embedding 
colored by cell subtype. b) Heatmap showing mean RNA expression values of each cluster, colored by a 
log2 scale. c) Diffusion map embedding of samples (colored by group assignment) revealing multiple 
trajectories that represent increasing relative frequency of selected cell populations. d) Summary 
histograms, each representing the bin-wise mean relative frequency of cell subtypes for all samples 
assigned to a given group. The sample IDs (as assigned in the original dataset published by Tirosh et al. 
(12)) of all samples in each inhibitor group can be found in Table S6.  
 
When comparing and mapping patient specimens, PhEMD identified the 
specimen ‘Mel75’ as having a unique immune cell profile characterized by the greatest 
proportion of exhausted CD8+ T-cells. These cell-state and tumor-comparison findings 
corroborated previously published results on the immune cell subtypes and inter-
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specimen heterogeneity present in this cohort (12). In addition to confirming prior 
findings, this analysis yielded an embedding that revealed the manifold structure of the 
single-cell specimen state space. With respect to a reference group of biospecimens 
(Cluster D) that were comprised mostly of CD4+ T-cells and were mapped to one part of 
the manifold, three axes of variation emerged that corresponded to increasing relative 
proportions of B-cells (C-5, C-6), macrophages (C-7), and exhausted CD8+ T-cells (C-1) 
(Figure 14C-D, Table S6). While it was well-understood that a set of individual cells, 
such as those undergoing differentiation, may demonstrate manifold structure (56, 89), 
our PhEMD embedding suggested that a set of patients with a shared phenotype (e.g., 
melanoma) may also lie on a continuous manifold (90). 
To further explore this concept, we applied PhEMD to a mass cytometry dataset 
containing the T-cell infiltrates of 75 clear cell renal cell carcinoma (ccRCC) 
specimens (13). At the cellular level, our analysis recapitulated previous findings of 
important T-cell subpopulations present (13). Cell subtype C-1 represented cells with 
absent or low expression of both CD4 and CD8. C-2 through C-4 represented CD4+ T-
cells with increasing expression of CD4, CD7, CCR7 and FOXP3, consistent with a 
regulatory T-cell profile. C-5 represented CD4+ T-cells with high Ki-67, a well-known 
proliferative marker. C-8 represented CD8+ cells with high expression of CD11b and 
CD45RA.The trajectory from C-6 to C-7 to C-9 to C-10 represented CD8+ T-cells with 
increasing expression of CD8, CD38, CD86, Ki-67, Tim-3, and PD-1. C-9 and C-10 cells 
demonstrated the highest expression of the above markers, consistent with a T-cell 
exhaustion profile (Figure 15A-B) (87). 
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Figure 15. PhEMD applied to mass cytometry data of 75 ccRCC samples gated for T-cells. a) PHATE 
embedding of T-cell manifold colored by cell subtype. b) Heatmap showing mean protein expression values 
of each cell subtype cluster, colored by a log2 scale. c) Diffusion map embedding of all tumors colored by 
tumor subgroup, defined by hierarchical clustering. The main axes of inter-sample variability are 
highlighted as dotted-black trajectories. d) Summary histograms, each representing the bin-wise mean 
relative frequency of cell subtypes for all samples assigned to a given group. The sample IDs (as assigned 
in the original publication of these data (13)) of all samples in each inhibitor group can be found in Table 
S7. 
We then modeled the diversity in immune cell signatures as a tumor-specimen 
embedding that could be used to characterize specimen-to-specimen variation (Figure 
15C). A group of tumor specimens (Cluster B) mapping to one end of the PhEMD 
embedding was characterized by a marked predominance of CD4+ T-cells (C-2, C-3), and 
progression toward the other end of the tumor-space manifold represented a relative 
decrease in CD4+ T-cells and marked relative increase in CD8+ PD1+ exhausted T-cells 
(C-9, C-10) (Figure 15C, Table S7). This finding was supported by the initial report of 
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substantial inter-patient variability in T-cell profiles especially related to CD8+ cells (13). 
The detection of a subset of patients with exhausted T-cell enrichment may be of 
particular clinical interest, as immunotherapy agents that combat T-cell exhaustion have 
become a mainstay of advanced-stage ccRCC treatment, but patients continue to have 
highly variable treatment responses (91, 92). Future single-cell tumor-profiling 
experiments assessing treatment response may be able to use PhEMD as a tool to identify 




Here, we have demonstrated the successful mapping of single-cell experimental 
conditions using our proposed PhEMD embedding technique. We extensively studied the 
Py2T murine breast cancer cell line treated with TGF-b1 and perturbed with over 200 
kinase inhibitors, measured using mass cytometry. In this experiment, PhEMD revealed 
the structure of the kinase inhibitor space based on each drug’s effect on the Py2T cell 
populations undergoing EMT. The final embedding of inhibitors was found to have low-
dimensional structure, with drugs mapping to one of three main axes. We have shown 
that the embedding produced by PhEMD is useful in several ways: 
1. Visualizing the experimental variable (i.e., single-cell specimen) state space. 
2. Identifying clusters of similar experimental variable settings (e.g., similar drugs 
with respect to their measured effects on a given cell population). 
3. Characterizing axes of variability among specimens in terms of biologically-
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interpretable differences in the types and abundances of cell subpopulations 
present. 
4. Extending the experimental variable state space through inference of unmeasured 
experimental settings based on similarity to existing (measured) settings. 
PhEMD can enable a new paradigm of searching for effective therapeutic agents by 
identifying a small subset drugs that collectively capture the network geometry of a larger 
drug set. We demonstrated this application by computing a dictionary of 34 experimental 
conditions and showing that these experimental conditions were sufficient to capture the 
network geometry of the 300-specimen state space. This finding has the potential to 
reduce experimental burden in future drug discovery efforts. For example, one can first 
apply PhEMD to measurements obtained using one profiling technique (e.g., mass 
cytometry) to identify a small set of dictionary specimens from a large set of candidates 
and then investigate this smaller set further using complementary technologies that may 
be more limited in scale (e.g., single-cell RNA sequencing). 
The PhEMD embedding can be integrated with additional data sources and data 
types for even larger and richer analyses. By using drug-target specificity data from a 
complementary inhibitor profiling experiment along with data imputation approaches, we 
were able to accurately predict the effects of inhibitors not directly measured in our 
experiment on TGFβ1-induced breast cancer EMT. This approach is useful for analyzing 
drug-screen experiments, as it enables an initial mapping of a modest set of drugs (e.g., 
dictionary points) measured with single-cell resolution to be extended to include 
additional drugs. This application is not limited to perturbation screen data and can be 
useful for imputing the phenotypes of specimens (of any type) that are not directly 
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measured using single-cell profiling. For example, examining a cohort of patients in 
which only some patients were biopsied and genomically profiled, one could potentially 
incorporate a non-genomic based measure of patient–to-patient similarity (e.g., based on 
clinicopathologic features) to predict the single cell-based phenotypes of all patients in 
the cohort. 
We explored the applicability of PhEMD to other experimental designs besides 
drug screens by applying it to single-cell data from two clinical tumor-biopsy cohorts. 
These analyses revealed that PhEMD can uncover manifold structure in the tumor-
specimen space that is biologically meaningful based on the observed proportions of the 
specimens’ cell subpopulations. When applied to the melanoma and ccRCC datasets, 
PhEMD revealed “trajectories” of patients, with the most notable axis in both datasets 
consisting of patients with an increasing proportion of exhausted CD8+ T-cells. It is 
possible that the abundance of tumor-infiltrating, exhausted T-cells may predict response 
to immunotherapy, although additional studies are needed to assess this. The PhEMD 
method may be useful for developing personalized cancer treatment regimens involving 
immunotherapy. 
This study is not without limitations. Our approach specifically compares cell 
subtype relative abundances among biospecimens, which entails normalizing each 
biospecimen by its total cell count. In this setting, since relative abundances by definition 
sum to one for each biospecimen, the Earth Mover’s Distance is a true metric and is 
robust across all pairwise comparisons of biospecimens. Comparing cell subtype relative 
abundances rather than absolute abundances is also often preferable from a biological 
perspective, as biospecimens (e.g., biopsy samples) may demonstrate variation in cell 
 72 
yield that is a technical artifact of little biological interest. Nevertheless, there exist 
experimental scenarios in which cell yield is of biological importance. In future work, we 
aim to incorporate cell yield into specimen-to-specimen comparisons and into the final 
biospecimen embedding. Another area of active investigation is exploring alternative 
methods of embedding the cell-subtype and biospecimen-state space. In the presented 
experiments, PHATE was used to model the cell-subtype space and diffusion maps were 
used to generate the biospecimen-state space. Future work may assess the utility of other 
methods that are potentially applicable for these tasks. 
In the present study, PhEMD was used to characterize mass cytometry and single-
cell RNA-sequencing data, though PhEMD may be applied to data generated by other 
single-cell profiling platforms as well. Many experimental designs may benefit from 
PhEMD—for example, comparisons of specimens pre- and post-treatment (or receiving 
different treatments), time-series analyses of cells undergoing transition processes, and 
organization of heterogeneous-yet-related specimens for the purpose of disease 
subtyping. Additionally, applying PhEMD to large-scale functional genomics (e.g., 
single-cell CRISPR) screens may yield embeddings that reveal complex relationships 
between genes. We have demonstrated in our analysis of over 1.7 million cells across 300 
specimens and five mass cytometry runs that PhEMD is highly scalable and robust to 
batch effect. PhEMD offers the efficiency, flexibility, and model interpretability 
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Table S1. List of inhibitors included in EMT drug-screen experiment. 
Compound in DMSO Cas Number  Reported Target Catalog Number Plate / Well 
Axitinib 319460-85-0 VEGFR, PDGFR, c-Kit S1005 A / B2 
Dovitinib (TKI-258) 405169-16-6, 804551-71-1 FLT3 S1018 A / B3 
Lapatinib Ditosylate 
(Tykerb) 
388082-77-7, 231277-92-2 (free base), 1187538-
35-7 (4-methylbenzenesulfonate) EGFR, HER2 S1028 A / B4 
Sorafenib (Nexavar) 475207-59-1, 284461-73-0 (free base) VEGFR, PDGFR, Raf S1040 A / B5 
BMS-599626 (AC480) 714971-09-2, 873837-23-1 (HCl), 873837-22-0 (H2O) EGFR, HER2 S1056 A / B6 
SB 203580 152121-47-6, 224047-03-4, 869185-85-3 (HCl) p38 MAPK S1076 A / B7 
KU-55933 587871-26-9 ATM S1092 A / B8 
LY294002 154447-36-6, 934389-88-5 (HCl) PI3K S1105 A / B9 
JNJ-38877605 943540-75-8, 1093204-17-1 (X methanesulfonate), 1093204-20-6 (XHCl) c-Met S1114 A / B10 
Brivanib alaninate 
(BMS-582664) 649735-63-7 VEGFR S1138 A / B11 
Saracatinib (AZD0530) 379231-04-6, 893428-72-3 (Fumaric acid), 893428-71-2 (3H2O) Src, Bcr-Abl S1006 A / C2 
CI-1033 (Canertinib) 267243-28-7, 289499-45-2 (2HCl) EGFR, HER2 S1019 A / C3 
Motesanib Diphosphate 
(AMG-706) 
857876-30-3, 453562-69-1 (free base), 945716-97-
2 (H2O) VEGFR, PDGFR, c-Kit S1032 A / C4 
Sunitinib Malate 
(Sutent) 
341031-54-7, 557795-19-4 (free base), 1126641-
10-8 ( Maleic acid) VEGFR, PDGFR, c-Kit, Flt S1042 A / C5 
Masitinib (AB1010) 790299-79-5, 1048007-93-7 (methanesulfonate) c-Kit, PDGFR, FGFR, FAK S1064 A / C6 
SB 202190 152121-30-7, 350228-36-3 (HCl) p38 MAPK S1077 A / C7 
GSK1904529A 1089283-49-7 IGF-1R S1093 A / C8 
OSU-03012 742112-33-0 PDK-1 S1106 A / C9 
PD 0332991 
(Palbociclib) HCl 827022-32-2, 571190-30-2 (free base) CDK S1116 A / C10 
AG-490 133550-30-8 JAK, EGFR S1143 A / C11 
 2 
AZD6244 (Selumetinib) 606143-52-6, 942275-12-9 (4-methylbenzenesulfonate) MEK S1008 A / D2 
CI-1040 (PD184352) 212631-79-3 MEK S1020 A / D3 
Nilotinib (AMN-107) 641571-10-0 Bcr-Abl S1033 A / D4 
Tandutinib (MLN518) 387867-13-2, 1227636-16-9 (3H2O) Flt S1043 A / D5 
GDC-0941 957054-30-7, 957054-33-0 (dimethanesulfonate), 957054-54-5 (xTFA) PI3K S1065 A / D6 
MK-2206 2HCl 1032350-13-2, 1032349-93-1 (free base), 1032349-77-1 (HCl) Akt S1078 A / D7 
PF-04217903 956905-27-4, 956906-93-7 (methanesulfonate), 1159490-81-9 (HCl) c-Met S1094 A / D8 
Danusertib (PHA-
739358) 827318-97-8 
Aurora Kinase, FGFR, Bcr-Abl, 
c-RET, Src S1107 A / D9 
Triciribine (Triciribine 
phosphate) 35943-35-2 Akt S1117 A / D10 
SNS-032 (BMS-
387032) 345627-80-7, 345627-90-9 (HCl) CDK S1145 A / D11 
BIBF1120 (Vargatef) 656247-17-5, 790241-30-4 (methanesulfonate), 959761-73-0 (HCl) VEGFR, PDGFR, FGFR S1010 A / F2 
Deforolimus 
(Ridaforolimus) 572924-54-0, 697252-87-2 mTOR S1022 A / F3 
PD0325901 391210-10-9, 870474-62-7 MEK S1036 A / F4 
Vandetanib (Zactima) 443913-73-3, 338992-53-3 (TFA), 524722-52-9 (HCl) VEGFR S1046 A / F5 
Crizotinib (PF-
02341066) 877399-52-5, 877399-53-6 (acetate) c-Met, ALK S1068 A / F6 
SU11274 658084-23-2 c-Met S1080 A / F7 
Vatalanib 2HCl 
(PTK787) 212141-51-0, 212141-54-3 (free base) VEGFR, c-Kit, Flt S1101 A / F8 
BI 2536 755038-02-9, 876126-71-5 (H2O) PLK S1109 A / F9 
XL-184 (Cabozantinib) 849217-68-1,1140909-48-3 (L-(-)-Apple Acid) VEGFR, c-Met, Flt, Tie-2, c-Kit S1119 A / F10 
PLX-4720 918505-84-7 Raf S1152 A / F11 
Afatinib (BIBW2992) 439081-18-2, 936631-70-8 (Maleic acid), 1254955-21-9 (XHCl) EGFR, HER2 S1011 A / G2 
 3 
Erlotinib HCl 183319-69-9, 183321-74-6 (free base), 248594-19-6 (methanesulfonate) EGFR S1023 A / G3 
VX-680 (MK-0457, 
Tozasertib) 639089-54-6, 639090-58-7 (sulfate) Aurora Kinase S1048 A / G5 
PHA-665752 477575-56-7, 1262750-60-6(HCl) c-Met S1070 A / G6 
Brivanib (BMS-540215) 649735-46-6 VEGFR S1084 A / G7 
U0126-EtOH 1173097-76-1, 109511-58-2 (FREE BASE) MEK S1102 A / G8 
Foretinib 
(GSK1363089, XL880) 849217-64-7, 1332889-22-1 (H2O) c-Met, VEGFR S1111 A / G9 
Everolimus (RAD001) 159351-69-6, 1245613-55-1 mTOR S1120 A / G10 
Roscovitine (Seliciclib, 
CYC202)  186692-46-6 CDK S1153 A / G11 
CP-724714 537705-08-1 EGFR, HER2 S1167 B / B2 
ENMD-2076 1291074-87-7 Flt, Aurora Kinase, VEGFR S1181 B / B3 
Amuvatinib (MP-470) 850879-09-3 c-Met, c-Kit, PDGFR, Flt, c-RET S1244 B / B4 
AMG-208 1002304-34-8  c-Met S1316 B / B5 
AS-605240 648450-29-7 PI3K S1410 B / B6 
AS703026 (pimasertib) 1236699-92-5, 1236361-78-6 (HCl) MEK S1475 B / B7 
CCT129202 942947-93-5 Aurora Kinase S1519 B / B8 
R406 (free base) 841290-80-0 Syk S1533 B / B9 
KU-60019 925701-49-1 ATM S1570 B / B10 
KW 2449 1000669-72-6 Flt, Bcr-Abl, Aurora Kinase S2158 B / B11 
TGX-221 663619-89-4 PI3K S1169 B / C2 
PIK-90 677338-12-4 677338-12-4 S1187 B / C3 
JNJ-7706621 443797-96-4 CDK, Aurora Kinase S1249 B / C4 
TG100-115 677297-51-7, 677297-55-1 (2HCL) PI3K S1352 B / C5 
Staurosporine 62996-74-1 PKC S1421 B / C6 
SB 525334 356559-20-1 TGF-beta/Smad S1476 B / C7 
 4 
XL765 1349796-36-6, 1123889-87-1 PI3K, mTOR S1523 B / C8 
CP 673451 343787-29-1, 343787-32-6 (4-methylbenzenesulfonate) PDGFR S1536 B / C9 
BS-181 HCl 1092443-52-1 (free base) CDK S1572 B / C10 
WZ3146 1214265-56-1 EGFR S1170 B / D2 
PIK-75 372196-77-5, 372196-67-3 (free base) PI3K, DNA-PK S1205 B / D3 
PD173074 219580-11-7 FGFR S1264 B / D4 
GSK1059615 958852-01-2, 1356195-42-0 (H2O . Na) PI3K, mTOR S1360 B / D5 
Aurora A Inhibitor I 1158838-45-9 Aurora Kinase S1451 B / D6 
HMN-214 173529-46-9 PLK S1485 B / D7 
AT7519 844442-38-2, 902135-91-5 (HCl), 902135-89-1 (methanesulfonate) CDK S1524 B / D8 
AZD8055 1009298-09-2, 1201799-04-3 (D(-)-Tartaric Acid), 1201799-05-4 (Fumaric acid) mTOR S1555 B / D9 
BIRB 796 
(Doramapimod) 285983-48-4, 1283526-53-3 (HCl) p38 MAPK S1574 B / D10 
LY2784544 1229236-86-5, 1229236-87-6 (HCl) JAK S2179 B / D11 
WZ4002 1213269-23-8 EGFR S1173 B / F2 
YM201636 371942-69-7, 371933-96-9 (2HCl) PI3K S1219 B / F3 
Vemurafenib 
(PLX4032) 918504-65-1 Raf S1267 B / F4 
ON-01910 1225497-78-8 PLK S1362 B / F5 
Thiazovivin 1226056-71-8, 1228446-06-7 (TFA) ROCK S1459 B / F6 
PHA-793887 718630-59-2, 718630-60-5 (HCl) CDK S1487 B / F7 
Hesperadin 422513-13-1 Aurora Kinase S1529 B / F8 
KRN 633 286370-15-8 VEGFR, PDGFR S1557 B / F9 
TWS119 601514-19-6 GSK-3 S1590 B / F10 
AST-1306 1050500-29-2, 897383-62-9 (free base) EGFR S2185 B / F11 
PD98059 167869-21-8 MEK S1177 B / G2 
 5 
OSI-930 728033-96-3 c-Kit, VEGFR S1220 B / G3 
IC-87114 371242-69-2 PI3K S1268 B / G4 
Ki8751 228559-41-9 VEGFR, c-Kit, PDGFR S1363 B / G5 
SP600125 129-56-6, 67072-00-8 (potassium salt) JNK S1460 B / G6 
PIK-93 593960-11-3 PI3K, VEGFR S1489 B / G7 
BIX 02188 1094614-84-2 MEK S1530 B / G8 
AT7867 857531-00-1 Akt, S6 kinase S1558 B / G9 
BMS-265246 582315-72-8 CDK S2014 B / G10 
AZD8931 848942-61-0, 1196531-39-1 (diFumaric acid) EGFR, HER2 S2192 B / G11 
Raf265 derivative 927880-90-8 VEGFR, Raf S2200 C / B2 
PP242 1092351-67-1, 1173019-76-5 (H2O) mTOR S2218 C / B3 
Palomid 529 914913-88-5 PI3K S2238 C / B4 
TAK-733 1035555-63-5 MEK S2617 C / B5 
DCC-2036 (Rebastinib) 1020172-07-9, 1020172-08-0 (2HCl), 1033893-29-6 (4-methylbenzenesulfonate) Bcr-Abl S2634 C / B6 
AS-252424 900515-16-4 PI3K S2671 C / B7 
NVP-BSK805 1092499-93-8 (free base) JAK S2686 C / B8 
AMG 900 945595-80-2 Aurora Kinase S2719 C / B9 
AZ628 878739-06-1 Raf S2746 C / B11 
BMS 794833 1174046-72-0, 1174161-83-1 (HCl) c-Met, VEGFR S2201 C / C2 
Cyt387 1056634-68-4, 1056636-08-8 (XHCl) JAK S2219 C / C3 
WP1130 856243-80-6 DUB, Bcr-Abl S2243 C / C4 
LDN193189 1062368-24-4, 1062368-62-0 (HCl) TGF-beta/Smad S2618 C / C5 
CCT128930 885499-61-6 Akt S2635 C / C6 
PF-00562271 939791-38-5, 717907-75-0 (free base), 939791-39-6 (methanesulfonate) FAK S2672 C / C7 
WAY-600 1062159-35-6 mTOR S2689 C / C8 
ZM 336372 208260-29-1 Raf S2720 C / C9 
 6 
TG101348 
(SAR302503) 936091-26-8, 1374744-69-0 (2ClH.H2O) JAK S2736 C / C10 
AMG458 913376-83-7  c-Met S2747 C / C11 
NVP-BHG712 940310-85-0 VEGFR, Src, Raf, Bcr-Abl S2202 C / D2 
SB590885 405554-55-4  Raf S2220 C / D3 
BKM120 (NVP-
BKM120) 
944396-07-0, 1312445-63-8 (HCl), 1370351-44-2 
(0.5H2O) PI3K S2247 C / D4 
AZD5438 602306-29-6 CDK S2621 C / D5 
A66 1166227-08-2 PI3K S2636 C / D6 
GSK1120212 
(Trametinib) 871700-17-3, 871702-06-6 (sodium salt) MEK S2673 C / D7 
TG101209 936091-14-4 Flt, JAK, c-RET S2692 C / D8 
PF-03814735 942487-16-3 Aurora Kinase S2725 C / D9 
PKI-402 1173204-81-3, 1173204-82-4 (XHCl) PI3K S2739 C / D10 




1025687-58-4, 901119-35-5 (free base),1180490-
89-4 (acetate) Syk S2206 C / F2 
CAL-101 (GS-1101) 870281-82-6 PI3K S2226 C / F3 
Indirubin 479-41-4 GSK-3 S2386 C / F4 
OSI-027 936890-98-1, 1187559-66-5 (sodium salt) mTOR S2624 C / F5 
GSK2126458 1086062-66-9 PI3K, mTOR S2658 C / F6 
PCI-32765 (Ibrutinib) 936563-96-1 Src S2680 C / F7 




1110813-31-4, 1042385-75-0 (H2O) EGFR S2727 C / F9 
PHA-767491 845714-00-3, 942425-68-5 (HCl) CDK S2742 C / F10 
Arry-380 937265-83-3 HER2 S2752 C / F11 
PIK-293 900185-01-5 PI3K S2207 C / G2 
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PIK-294 900185-02-6 PI3K S2227 C / G3 
Quercetin (Sophoretin) 117-39-5 PI3K, PKC, Src, Sirtuin S2391 C / G4 
R788 (Fostamatinib) 901119-35-5 Syk S2625 C / G5 
WYE-125132 1144068-46-1 mTOR S2661 C / G6 
AS-604850 648449-76-7 PI3K S2681 C / G7 
KX2-391 897016-82-9, 1038395-65-1 (2HCl), 1080645-95-9 (methanesulfonate), 1201926-60-4 (Maleic acid) Src S2700 C / G8 
AG-1478 (Tyrphostin 
AG-1478) 153436-53-4, 170449-18-0 (HCl) EGFR S2728 C / G9 
PF-04691502 1013101-36-4 mTOR, PI3K, Akt S2743 C / G10 
ARQ 197 (Tivantinib) 905854-02-6, 1000873-98-2, 1228508-24-4 c-Met S2753 C / G11 
NVP-BVU972 1185763-69-2 c-Met S2761 D / B2 
TAK-285 871026-44-7, 871027-78-0 (methanesulfonate) EGFR S2784 D / B3 
GDC-0068 1001264-89-6 Akt S2808 D / B4 
Desmethyl Erlotinib 
(CP-473420) 183321-86-0, 183320-51-6 (HCl) EGFR S2826 D / B5 
 TG 100713 925705-73-3 PI3K S2870 D / B6 
Wortmannin 19545-26-7, 1405-03-4 PI3K S2758 D / B7 
AZD2014 1009298-59-2 mTOR S2783 D / B8 
Dabrafenib 
(GSK2118436) 
1195765-45-7, 1195768-06-9 (methanesulfonic 
acid) Raf S2807 D / B9 
TPCA-1 507475-17-4 IKK S2824 D / B10 
WHI-P154 211555-04-3, 296234-84-9 (HCl) JAK S2867 D / B11 
CH5424802 1256580-46-7, 1256589-74-8 (HCl) ALK S2762 D / C2 
INCB28060 1029712-80-8, 1029714-89-3 (XHCl), 1197376-85-4 (2HCl) c-Met S2788 D / C3 
INK 128 (MLN0128) 1224844-38-5 mTOR S2811 D / C4 
Torin 1 1222998-36-8 mTOR S2827 D / C5 
Piceatannol 10083-24-6, 21100-92-5 Syk S3026 D / C6 
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Dinaciclib 
(SCH727965) 779353-01-4 CDK S2768 D / C7 
Sotrastaurin (AEB071) 425637-18-9, 1058706-32-3 (HCl), 1058706-35-6 (Maleic acid) PKC S2791 D / C8 
Tyrphostin AG 879 (AG 
879) 148741-30-4 HER2 S2816 D / C9 
Semaxanib (SU5416) 194413-58-6 VEGFR S2845 D / C10 
VX-702 745833-23-2, 479543-46-9 p38 MAPK S6005 D / C11 
3-Methyladenine 5142-23-4, 80681-18-1(HCl) PI3K S2767 D / D2 
Tofacitinib (CP-690550, 
Tasocitinib) 477600-75-2, 540737-29-9 (citrate) JAK S2789 D / D3 
BYL719 1217486-61-7 PI3K S2814 D / D4 
SAR131675 1433953-83-3 VEGFR S2842 D / D5 
Tofacitinib citrate (CP-
690550 citrate) 540737-29-9, 477600-75-2 (free base) JAK S5001 D / D6 
MK-2461 917879-39-1, 1196681-15-8, 1170702-87-0 (sodium salt) c-Met S2774 D / D7 
CEP33779 1257704-57-6 JAK S2806 D / D8 
Tideglusib 865854-05-3  GSK-3 S2823 D / D9 
IMD 0354 978-62-1, 634914-41-3 (sodium salt ) IKK S2864 D / D10 
Dovitinib Dilactic acid 
(TKI258 Dilactic acid)  852433-84-2, 405169-16-6 (free base) FLT3 S2769 D / F2 
WP1066 857064-38-1 JAK S2796 D / F3 
Torin 2 1223001-51-1 mTOR S2817 D / F4 
Baricitinib 
(LY3009104,incb28050) 1187594-09-7, 1187594-10-0 (TFA) JAK S2851 D / F5 
MK-5108 (VX-689) 1010085-13-8 Aurora Kinase S2770 D / G2 
AZD4547 1035270-39-3 FGFR S2801 D / G3 
NVP-TAE226 761437-28-9 FAK S2820 D / G4 
Golvatinib (E7050) 928037-13-2 , 1007601-96-8 (L(+)-Tartaric Acid), 1007601-91-3 (Fumaric acid) c-Met S2859 D / G5 
Linifanib (ABT-869) 796967-16-3 PDGFR, VEGFR S1003 E / B2 
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Cediranib (AZD2171) 288383-20-0 VEGFR, Flt S1017 E / B3 
Imatinib Mesylate 220127-57-1 PDGFR, c-Kit, Bcr-Abl S1026 E / B4 
Rapamycin (Sirolimus) 53123-88-9 mTOR S1039 E / B5 
Enzastaurin (LY317615) 170364-57-5 PKC S1055 E / B6 
SB 216763 280744-09-4 GSK-3 S1075 E / B7 
Linsitinib (OSI-906) 867160-71-2 IGF-1R S1091 E / B8 
GDC-0879 905281-76-7 Raf S1104 E / B9 
GSK690693 937174-76-0 Akt S1113 E / B10 
AT9283 896466-04-9 Bcr-Abl, JAK, Aurora Kinase S1134 E / B11 
BEZ235 (NVP-
BEZ235) 915019-65-7 mTOR, PI3K S1009 E / C2 
Dasatinib (BMS-
354825) 302962-49-8 Src, Bcr-Abl, c-Kit S1021 E / C3 
Pazopanib HCl 635702-64-6 VEGFR, PDGFR, c-Kit S1035 E / C4 
Temsirolimus (Torisel) 162635-04-3 mTOR S1044 E / C5 
SB 431542 301836-41-9 TGF-beta/Smad S1067 E / C6 
PD153035 HCl 183322-45-4 EGFR S1079 E / C7 
MLN8054 869363-13-3 Aurora Kinase S1100 E / C8 
TAE684 (NVP-
TAE684) 761439-42-3 ALK S1108 E / C9 
XL147 956958-53-5 PI3K S1118 E / C10 
Barasertib (AZD1152-
HQPA) 722544-51-6 Aurora Kinase S1147 E / C11 
Bosutinib (SKI-606) 380843-75-4 Src S1014 E / D2 
Gefitinib (Iressa) 184475-35-2 EGFR S1025 E / D3 
PI-103 371935-74-9 DNA-PK, PI3K, mTOR S1038 E / D4 
Y-27632 2HCl 129830-38-2 ROCK S1049 E / D5 
ZSTK474 475110-96-4 PI3K S1072 E / D6 
NVP-ADW742 475488-23-4 IGF-1R S1088 E / D7 
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ZM-447439 331771-20-1 Aurora Kinase S1103 E / D8 
SGX-523 1022150-57-7 c-Met S1112 E / D9 
MLN8237 (Alisertib) 1028486-01-2 Aurora Kinase S1133 E / D10 
SNS-314 1146618-41-8 Aurora Kinase S1154 E / D11 
E7080 (Lenvatinib) 417716-92-8 VEGFR S1164 E / F2 
WZ8040 1214265-57-2 EGFR S1179 E / F3 
AG-1024  65678-07-1 IGF-1R S1234 E / F4 
BX-912 702674-56-4 PDK-1 S1275 E / F5 
Pelitinib (EKB-569) 257933-82-7 EGFR S1392 E / F6 
TSU-68 252916-29-3 VEGFR, PDGFR , FGFR S1470 E / F7 
LY2228820 862507-23-1 p38 MAPK S1494 E / F8 
AZD7762 860352-01-8 Chk S1532 E / F9 
PD318088 391210-00-7 MEK S1568 E / F10 
Neratinib (HKI-272) 698387-09-6 HER2, EGFR S2150 E / F11 
CYC116 693228-63-6 Aurora Kinase, VEGFR S1171 E / G2 
Tivozanib (AV-951) 475108-18-0 VEGFR, c-Kit, PDGFR S1207 E / G3 
WYE-354 1062169-56-5 mTOR S1266 E / G4 
MGCD-265 875337-44-3 c-Met, VEGFR, Tie-2 S1361 E / G5 
PHA-680632 398493-79-3 Aurora Kinase S1454 E / G6 
AEE788 (NVP-
AEE788) 497839-62-0 EGFR, Flt, VEGFR, HER2 S1486 E / G7 
Quizartinib (AC220) 950769-58-1 Flt S1526 E / G8 
PHT-427 1191951-57-1 Akt S1556 E / G9 
Tie2 kinase inhibitor 948557-43-5 Tie-2 S1577 E / G10 
BGJ398 (NVP-BGJ398) 872511-34-7 FGFR S2183 E / G11 
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Table S2. List of antibodies included in EMT drug-screen experiment. 









User Clone Validation 




























4.9 30 min vanadate treatment, 








WB, IP, FC CST 2 https://www.cellsignal.com/products/primary
-antibodies/phospho-shp-2-tyr580-d66f10-
rabbit-mab/5431 





WB CST 5 https://www.cellsignal.com/products/primary
-antibodies/phospho-fak-tyr397-
antibody/3283?site-search-type=Products 
2.5 5 Days 4 ng/mL  TGFb vs 
5 Days Untreated 









4 30 min 4 ng/mL TGFb + 
Dabrafenib, AZ628 (bRaf, 
cRaf inhibitors) vs 30 min 
4 ng/mL TGFb 









4 3 Days 4 ng/mL  TGFb vs 





WB, IF, FC CST 7 https://www.cellsignal.com/products/primary
-antibodies/c-myc-d84c12-rabbit-
mab/5605?site-search-type=Products 










5 3 Days 4 ng/mL  TGFb vs 
3 Days Untreated 

















IHC-P, WB, Abcam NA 
https://www.abcam.com/NF-kB-p65-
antibody-ChIP-Grade-ab7970.html 3 













4 30 min vanadate treatment, 







WB, IP, ICH CST 18 https://www.cellsignal.com/products/primary
-antibodies/phospho-ampka-thr172-40h9-
rabbit-mab/2535 
4 30 min vanadate treatment, 












5 30 min 4 ng/mL TGFb +  
GDC09411 (PI3K 












2 30 min 4 ng/mL TGFb +  
PD325901 (MEK1/2 






















1 30 min 4 ng/mL TGFb + 
MK2260 (AKT inhibitor) 






WB, IF, FC CST 9516BF https://www.cellsignal.com/products/primary
-antibodies/phospho-smad1-5-ser463-465-
41d10-rabbit-mab/9516 
6 Not validated by user 
Gd160 CD44 IM7 Human; 
Mouse 





0.085 3 Days 4 ng/mL  TGFb vs 
3 Days Untreated 







1 3 Days 4 ng/mL  TGFb vs 









WB CST 5 https://www.cellsignal.com/products/primary
-antibodies/phospho-smad2-ser465-467-
smad3-ser423-425-d27f4-rabbit-mab/8828 
2 30 min 4 ng/mL TGFb + 
SB431542 (TGFßR 
inhibitor) vs 30 min 4 
ng/mL TGFb 
Ho165 ß-Catenin D13A1 Human; 
Mouse 
WB, IP, 





2 3 Days 4 ng/mL  TGFb vs 







WB, IF, FC CST 3 https://www.cellsignal.com/products/primary
-antibodies/phospho-marcks-ser167-170-
d13e4-xp-rabbit-mab/8722 
7 Not validated by user 
Er168 CD24 30-F1 Mouse  FC Biolegend 138502 https://www.biolegend.com/en-
us/products/purified-anti-mouse-cd24-
antibody-6616 
3 3 Days 4 ng/mL  TGFb vs 













5 30 min 4 ng/mL TGFb + 
PP121 (PDGFR inhibitor) 

























2 30 min 4ng/ mL TGFb + 1 
µM PD325901 vs 30 min 












5 5 Days Dinaciclib (1µM) + 
4ng/mL TGFß vs 5 Days 

























1 11 Days Untreated Py2T 





























Table S3. Clusters of inhibitors with similar effects in multiple-batch EMT drug-screen experiment. 
Cluster A Cluster B Cluster C Cluster D Cluster E Cluster F Cluster G Cluster H 




beta:Smad) AZ628 (Raf) AZD5438 (CDK) AMG 900 (Aurora Kinase) Cyt387 (JAK12) 
Untreated control Trametinib (MEK12) 
GSK2126458 
(PI3K) Afatinib (EGFR) 
Amuvatinib 
(cMet) Foretinib (c-Met) NVP-BGT226 (PI3K) Indirubin (GSK-3b) 
Untreated control Canertinib (EGFR) 
Erlotinib 
(EGFR) CI-1040 (MEK1:2) Torin1 (mTOR) 
Tozasertib (Aurora 





(VEGFR) Selumetinib (MEK1:2) AZD7762 (Chk) SP600125 (JNK12) 
PF-03814735 (Aurora 
KinaseAB) R935788 (Syk) 
Untreated control SB525334 (TGFbR1) 
AST-1306 
(EGFR) KW 2449 (Flt) BEZ235 (mTOR) Bosutinib (Bcr-Abl) TG101209 (Flt) Rebastinib (Bcr-Abl) 
Untreated control SB431542 (TGFR) 
AZD8931 
(EGFR) WZ3146 (EGFR) Dasatinib (Src) Pelitinib (EGFR) BI 2536 (PLK1) Deforolimus (mTOR) 
Saracatinib (Src)  
CP-473420 
(EGFR) IMD 0354 (IKKa)   AT9283 (AuroraK) Sunitinib (VEGFR) 
Untreated control  
WHI-P154 
(JAK3) PD153035 (EGFR)   Barasertib (AuroraK) Vandetanib (VEGFR) 
Untreated control  
AEE788 
(EGFR) PD318088 (MEK12)   CYC116 (AuroraK) AT7867 (Akt) 
Untreated control  
Gefitinib 
(EGFR) WZ8040 (EGFR)   MLN8054 (AuroraK-A) CP 673451 (PDGFRb) 
Untreated control      MLN8237 (AuroraK-A) Ki8751 (VEGFR) 
Untreated control      Neratinib (HER2) R406 (Syk) 
AS703026 
(MEK12)      Pazopanib (VEGFR1) Thiazovivin (ROCK) 
Untreated control      SNS314 (AuroraK-A) XL765 (PI3K) 
Untreated control      TAE684 (ALK) YM201636 (PI3K) 
Untreated control       CEP33779 (JAK2) 
Untreated control       CH5424802 (ALK) 
Untreated control       Dovitinib (FLT3) 
Untreated control       Semaxanib (VEGFR) 
Untreated control       Linifanib (PDGFRb) 
Untreated control       
LY2228820 
(p38MAPKa) 
Untreated control       Rapamycin (mTOR) 
Untreated control       Temsirolimus (mTOR) 
Untreated control       Tie2Kinhibitor (Tie2) 
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Cluster I Cluster J Cluster K Cluster L Cluster M Cluster N 
A-769662 (AMPK) BMS-599626 (EGFR) BKM120 (PI3K) Hesperadin (AuroraKinaseB) PIK-75 (PI3K) Torin2 (mTOR) 
A66 (PI3K) Lapatinib (EGFR) OSI-027 (mTOR) Dinaciclib (CDK2)   
AMG458 (c-Met) AZD8055 (mTOR) PKI-402 (PI3K)    
Arry-380 (HER2) HMN-214 (PLK1) PP242 (mTOR)    
AS-252424 (PI3K) ON-01910 (PLK1) WAY-600 (mTOR)    
AS-604850 (PI3K) PHA-793887 (CDK) GDC-0941 (PI3K)    
TGFb-only control Dabrafenib (b-Raf) MK-2206 (Akt123)    
BMS 794833 (c-Met) TAK-285 (EGFR) GSK1059615 (PI3K)    
CAL-101 (PI3K)  PIK-90 (PI3K)    
CCT128930 (Akt)  AZD2014 (mTOR)    
TGFb-only control  BYL719 (PI3K)    
TGFb-only control  INK128 (mTOR)    
TGFb-only control  PI-103 (PI3K, DNA-PK)    
TGFb-only control  WYE354 (mTOR)    
TGFb-only control  ZSTK474 (PI3K)    
Fostamatinib (Syk)      
KX2-391 (Src)      
NVP-BSK805 (JAK12)      
Palomid 529 (PI3K)      
PF-04691502 (mTOR)      
PHA-767491 (Cdc7:CDK9)      
PIK-293 (PI3K)      
PIK-294 (PI3K)      
Quercetin (PI3K)      
Raf265 (VEGFR)      
SB590885 (bRaf)      
TG101348 (JAK2)      
Tivantinib (c-Met)      
Tyrphostin (EGFR)      
WP1130 (DUB)      
WYE-125132 (mTOR)      
ZM 336372 (cRaf)      
AG-490 (JAK)      
Axitinib (VEGFR)      




Table S4. Cell yield of each experimental condition in EMT drug-screen experiment 
Dinaciclib (CDK2) 42 
PIK-75 (PI3K) 54 
SP600125 (JNK12) 82 
Tozasertib (Aurora Kinase) 98 
BI 2536 (PLK1) 129 
Hesperadin (AuroraKinaseB) 145 
HMN-214 (PLK1) 237 
IMD 0354 (IKKa) 257 
ON-01910 (PLK1) 288 
Foretinib (c-Met) 294 
Torin2 (mTOR) 298 
WZ3146 (EGFR) 384 
KW 2449 (Flt) 494 
AZD8055 (mTOR) 581 
Canertinib (EGFR) 617 
CYC116 (AuroraK) 630 
PIK-90 (PI3K) 631 
Afatinib (EGFR) 743 
GSK2126458 (PI3K) 755 
PD0325901 (MEK1:2) 803 
GSK1059615 (PI3K) 808 
Torin1 (mTOR) 826 
SNS314 (AuroraK-A) 853 
GDC-0941 (PI3K) 909 
Triciribine (Akt) 914 
PHA-793887 (CDK) 946 
Amuvatinib (cMet) 977 
AT9283 (Bcr-Abl) 1000 
MLN8237 (AuroraK-A) 1010 
Erlotinib (EGFR) 1025 
Everolimus (mTOR) 1028 
BEZ235 (mTOR) 1074 
AS703026 (MEK12) 1086 
MK-2206 (Akt123) 1087 
Barasertib (AuroraK) 1133 
Axitinib (VEGFR) 1155 
AMG 900 (Aurora Kinase) 1199 
ENMD-2076 (Flt) 1210 
AuroraA (inhibitor) 1263 
AZD2014 (mTOR) 1277 
AST-1306 (EGFR) 1318 
INK128 (mTOR) 1328 
AZD8931 (EGFR) 1339 
BMS-265246 (CDK1:cyclinB) 1347 
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Saracatinib (Src) 1409 
Deforolimus (mTOR) 1417 
PF-03814735 (Aurora KinaseAB) 1438 
BS-181 (CDK) 1445 
Untreated control 1457 
AZD7762 (Chk) 1592 
Vandetanib (VEGFR) 1598 
SB525334 (TGFbR1) 1650 
JNJ-7706621 (CDK1:CyclinB) 1711 
XL765 (PI3K) 1742 
CCT129202 (AuroraKinaseABC) 1751 
PD173074 (FGFR1) 1789 
Untreated control 1834 
Untreated control 1907 
Pelitinib (EGFR) 1908 
Vargatef (VEGFR) 1926 
CP-473420 (EGFR) 1939 
Crizotinib (c-Met) 1947 
AT7867 (Akt) 1985 
BYL719 (PI3K) 2011 
Untreated control 2032 
AMG-208 (c-Met) 2047 
NVP-BGT226 (PI3K) 2059 
LY2784544 (JAK2) 2080 
WZ4002 (EGFR) 2117 
CI-1040 (MEK1:2) 2141 
Untreated control 2152 
AT7519 (CDK1:cyclinB) 2156 
Untreated control 2158 
TGX-221 (PI3K) 2180 
Selumetinib (MEK1:2) 2205 
Lapatinib (EGFR) 2210 
BMS-599626 (EGFR) 2211 
Untreated control 2219 
Neratinib (HER2) 2250 
TWS119 (GSK3b) 2259 
KU-60019 (ATM) 2330 
KRN 633 (VEGFR) 2335 
CP-724714 (EGFR) 2359 
PD98059 (MEK12) 2363 
OSI-930 (cKit) 2376 
U0126 (MEK1:2) 2409 
Ki8751 (VEGFR) 2422 
IC-87114 (PI3K) 2445 
Palbociclib (CDK4:6) 2484 
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SNS-032 (CDK2:7:9) 2503 
BIRB 796 (p38MAPK) 2509 
Dasatinib (Src) 2510 
TG100-115 (PI3K) 2521 
YM201636 (PI3K) 2543 
PIK-93 (PI3K) 2559 
Motesanib (VEGFR) 2592 
Staurosporine (PKC) 2612 
BIX 02188 (MEK5) 2622 
Untreated control 2625 
Danusertib (Aurora Kinase) 2644 
PHA-665752 (c-Met) 2695 
KU-55933 (ATM) 2725 
Untreated control 2731 
SU11274 (c-Met) 2761 
LY294002 (PI3K) 2771 
Sunitinib (VEGFR) 2785 
TGFb-only control 2788 
Untreated control 2845 
Dovitinib (FLT3) 2866 
AZD5438 (CDK) 2888 
TGFb-only control 2909 
AS-605240 (PI3K) 2930 
TGFb-only control 2930 
R406 (Syk) 2942 
SB 203580 (p38 MAPK) 2972 
Masitinib (c-Kit) 2977 
Vemurafenib (bRAF) 2996 
TGFb-only control 3001 
TGFb-only control 3006 
Brivanib (VEGFR) 3014 
CP 673451 (PDGFRb) 3036 
OSU-03012 (PDK-1) 3053 
Vatalanib (VEGFR) 3055 
Sorafenib (VEGFR) 3075 
Roscovitine (CDK) 3080 
Tandutinib (Flt3) 3080 
TGFb-only control 3082 
PD153035 (EGFR) 3085 
ZSTK474 (PI3K) 3104 
Trametinib (MEK12) 3126 
Untreated control 3146 
Cabozantinib ( VEGFR2) 3187 
Nilotinib (Bcr-Abl) 3223 
Untreated control 3269 
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TGFb-only control 3282 
MLN8054 (AuroraK-A) 3290 
AEE788 (EGFR) 3297 
WHI-P154 (JAK3) 3330 
PLX-4720 (bRAF) 3343 
SB 202190 (p38 MAPK) 3361 
PI-103 (DNA-PK) 3383 
Untreated control 3425 
Thiazovivin (ROCK) 3441 
AG-490 (JAK) 3465 
PP242 (5Days) 3477 
PF-04217903 (c-Met) 3505 
Brivanib (VEGFR) 3563 
JNJ-38877605 (c-Met) 3622 
Untreated control 3656 
TGFb-only control 3668 
WYE354 (mTOR) 3672 
Temsirolimus (mTOR) 3698 
Pazopanib (VEGFR1) 3763 
PD318088 (MEK12) 3812 
TAE684 (ALK) 3875 
Wortmannin (PI3K) 3902 
GSK1904529A (IGF-1R) 3906 
TAK-285 (EGFR) 3918 
TGFb-only control 3948 
SB431542 (TGFR) 4021 
TG101209 (Flt) 4046 
TGFb-only control 4052 
NVP-BVU972 (c-Met) 4096 
CH5424802 (ALK) 4126 
TGFb-only control 4272 
TAK-733 (MEK12) 4280 
Untreated control 4287 
TGFb-only control 4321 
Rapamycin (mTOR) 4379 
TPCA-1 (IKK2) 4464 
TG100713 (PI3K) 4561 
GDC-0068 (Akt123) 4635 
SAR131675 (VEGFR) 4940 
WP1066 (JAK2) 4973 
PKI-402 (PI3K) 5139 
BKM120 (PI3K) 5148 
Dabrafenib (b) 5279 
WZ8040 (EGFR) 5283 
Untreated control 5294 
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LY2228820 (p38MAPKa) 5340 
NVP-ADW742 (IGF-1R) 5371 
Dovitinib (FLT3) 5387 
Gefitinib (EGFR) 5393 
TGFb-only control 5456 
Semaxanib (VEGFR) 5487 
TGFb-only control 5595 
TGFb-only control 5596 
MK-5108 (Aurora KinaseA) 5609 
TGFb-only control 5624 
Untreated control 5711 
AZD4547 (FGFR) 5713 
Tyrphostin (HER2) 5714 
Piceatannol (Syk) 5827 
TGFb-only control 5832 
NVP-TAE226 (FAK) 5860 
Untreated control 5874 
TGFb-only control 5902 
3-Methyladenine (PI3K) 5947 
Golvatinib (c-Met) 5966 
TGFb-only control 6028 
TGFb-only control 6101 
MK-2461 (c-Met) 6113 
Untreated control 6174 
Bosutinib (Src) 6247 
TGFb-only control 6262 
Tofacitinib (citrate) 6392 
INCB28060 (c-Met) 6412 
TGFb-only control 6445 
TGFb-only control 6454 
TGFb-only control 6515 
Tofacitinib (JAK3) 6555 
Dacomitinib (EGFR) 6561 
TGFb-only control 6633 
Tideglusib (GSK-3) 6677 
Sotrastaurin (PKC) 6685 
TGFb-only control 6688 
Untreated control 6695 
TGFb-only control 6789 
TGFb-only control 6793 
Baricitinib (JAK1) 6864 
Quizartinib (Flt3) 6942 
Ibrutinib (Src) 7074 
VX-702 (p38 MAPK) 7140 
MGCD-265 ( c-MET) 7228 
 6 
TGFb-only control 7335 
Cediranib (VEGFR) 7378 
Linsitinib (IGF-1R) 7397 
TGFb-only control 7443 
TGFb-only control 7610 
TGFb-only control 7667 
E7080 (VEGFR2) 7722 
TGFb-only control 8071 
OSI-027 (F5.csv) 8209 
CEP33779 (JAK2) 8214 
PHA680632 (AuroraK) 8257 
TGFb-only control 8275 
Tivozanib (VEGFR1) 8297 
Linifanib (PDGFRb) 8455 
BX912 (PDK-1) 8462 
GSK690693 (Akt1) 8986 
GDC0879 (B-Raf) 9309 
WAY-600 (mTOR) 9364 
ZM-447439 (AuroraK-A) 9415 
TGFb-only control 9670 
Enzastaurin (PKC) 9894 
PF-00562271 (FAK) 9920 
AG1024 (IGF-1R) 10343 
PHT427 (Akt) 10497 
Imatinib (PDGFR) 10597 
BGJ398 (FGFR1) 10677 
TSU68 (VEGFR1) 10677 
XL147 (PI3K) 11193 
Y-27632 (p160ROCK) 11615 
Tie2Kinhibitor (Tie2) 11676 
SGX523 (HGFR) 12691 
AS-604850 (PI3K) 12762 
A66 (PI3K) 12871 
PIK-293 (PI3K) 14011 
AZ628 (Raf) 14111 
SB216763 (GSK-3a) 14224 
TGFb-only control 14558 
PIK-294 (PI3K) 14641 
CAL-101 (PI3K) 14686 
Palomid 529 (PI3K) 14718 
R935788 (Syk) 14770 
WYE-125132 (mTOR) 14920 
LDN193189 (TGF-beta:Smad) 15493 
TGFb-only control 15640 
Tyrphostin (EGFR) 15705 
 7 
PF-04691502 (mTOR) 15787 
AMG458 (c-Met) 15862 
Untreated control 15898 
Fostamatinib (Syk) 15905 
Tivantinib (c-Met) 15933 
KX2-391 (Src) 16034 
Arry-380 (HER2) 16075 
BMS 794833 (c-Met) 16319 
A-769662 (AMPK) 16487 
TGFb-only control 16537 
Untreated control 16582 
Quercetin (PI3K) 16632 
ZM 336372 (cRaf) 16714 
TGFb-only control 17125 
TG101348 (JAK2) 17243 
NVP-BSK805 (JAK12) 17281 
Untreated control 17555 
Indirubin (GSK-3b) 17809 
Untreated control 18074 
Untreated control 18117 
WP1130 (DUB) 18293 
Raf265 (VEGFR) 18399 
SB590885 (bRaf) 18431 
TGFb-only control 18846 
TGFb-only control 18909 
NVP-BHG712 (VEGFR) 19703 
AS-252424 (PI3K) 21606 
CCT128930 (Akt) 22384 
Cyt387 (JAK12) 22753 
PHA-767491 (Cdc7:CDK9) 24855 




Table S5. Clusters of inhibitors with similar effects in single-batch EMT drug-screen experiment. 
 
Replicate 1 














(MEK12)  Dasatinib (Src) 
LY2228820 




control 3  
WZ8040 




control 4     Pelitinib (EGFR) MLN8237 (AuroraK-A) TGFb-only control 4  
Untreated 
control 5     Rapamycin (mTOR) Pazopanib (VEGFR1) TGFb-only control 5  
SB431542 
(TGFR)     Temsirolimus (mTOR) SNS314 (AuroraK-A) AG1024 (IGF-1R)  
     Tie2Kinhibitor (Tie2) TAE684 (ALK) BGJ398 (FGFR1)  
       BX912 (PDK-1)  
       Cediranib (VEGFR)  
       E7080 (VEGFR2)  
       Enzastaurin (PKC)  
       GDC0879 (B-Raf)  
       GSK690693 (Akt1)  
       Imatinib (PDGFR)  
       Linifanib (PDGFRb)  
       Linsitinib (IGF-1R)  
       MGCD-265 ( c-MET)  
       MLN8054 (AuroraK-A)  
       NVP-ADW742 (IGF-1R)  
       PHA680632 (AuroraK)  
       PHT427 (Akt)  
       Quizartinib (Flt3)  
       SB216763 (GSK-3a)  
       SGX523 (HGFR)  
       TSU68 (VEGFR1)  
       Tivozanib (VEGFR1)  
       XL147 (PI3K)  
       Y-27632 (p160ROCK)  





Cluster A Cluster B Cluster C Cluster D Cluster E Cluster F Cluster G Cluster H Cluster I 




(EGFR) Cediranib (VEGFR) AG1024 (IGF-1R) PI-103 (PI3K) 




(EGFR) Pelitinib (EGFR) 
Barasertib 
(AuroraK)  CYC116 (AuroraK) BGJ398 (FGFR1) 
WYE354 
(mTOR) 




Abl) AEE788 (EGFR) 
MLN8237 
(AuroraK-
A)  Linsitinib (IGF-1R) BX912 (PDK-1) 
ZSTK474 
(PI3K) 
Untreated control 4  Dasatinib (Src)  
SNS314 
(AuroraK-
A)  E7080 (VEGFR2) TGFb-only control 1  




MET) TGFb-only control 2  
SB431542 (TGFR)      
MLN8054 
(AuroraK-A) TGFb-only control 3  
      Rapamycin (mTOR) TGFb-only control 4  
      
Temsirolimus 
(mTOR) TGFb-only control 5  
      
Tivozanib 
(VEGFR1) Enzastaurin (PKC)  
      TSU68 (VEGFR1) GDC0879 (B-Raf)  
      XL147 (PI3K) GSK690693 (Akt1)  
       Imatinib (PDGFR)  
       Linifanib (PDGFRb)  
       
LY2228820 
(p38MAPKa)  
       
NVP-ADW742 (IGF-
1R)  
       Pazopanib (VEGFR1)  
       PHA680632 (AuroraK)  
       PHT427 (Akt)  
       Quizartinib (Flt3)  
       SB216763 (GSK-3a)  
       SGX523 (HGFR)  
       TAE684 (ALK)  
       Y-27632 (p160ROCK)  







Cluster A Cluster B Cluster C Cluster D Cluster E Cluster F Cluster G 
Untreated control 1 Gefitinib (EGFR) AEE788 (EGFR) AT9283 (AuroraK) Enzastaurin (PKC) TGFb-only control 1 PI-103 (PI3K) 
Untreated control 2 AZD7762 (Chk) WZ8040 (EGFR) Barasertib (AuroraK) Linsitinib (IGF-1R) TGFb-only control 2 WYE354 (mTOR) 
Untreated control 3 PD153035 (EGFR) Pelitinib (EGFR) CYC116 (AuroraK) LY2228820 (p38MAPKa) TGFb-only control 3 ZSTK474 (PI3K) 
Untreated control 4 PD318088 (MEK12) Neratinib (EGFR/HER2) 
MLN8237 (AuroraK-
A) MGCD-265 (c-MET) TGFb-only control 4  
Untreated control 5 Tie2Kinhibitor (Tie2) Bosutinib (Bcr-Abl) BEZ235 (mTOR) MLN8054 (AuroraK-A) TGFb-only control 5  
SB431542 (TGFR)  Cediranib (VEGFR)  SNS314 (AuroraK-A) AG1024 (IGF-1R)  
  Dasatinib (Src)  Tivozanib (VEGFR1) BGJ398 (FGFR1)  
    TSU68 (VEGFR1) BX912 (PDK-1)  
    XL147 (PI3K) E7080 (VEGFR2)  
     GDC0879 (B-Raf)  
     GSK690693 (Akt1)  
     Imatinib (PDGFR)  
     Linifanib (PDGFRb)  
     NVP-ADW742 (IGF-1R)  
     Pazopanib (VEGFR1)  
     PHA680632 (AuroraK)  
     PHT427 (Akt)  
     Quizartinib (Flt3)  
     Rapamycin (mTOR)  
     SB216763 (GSK-3a)  
     SGX523 (HGFR)  
     TAE684 (ALK)  
     Temsirolimus (mTOR)  
     Y-27632 (p160ROCK)  




Table S6. Clusters of biospecimens with similar single-cell profiles in melanoma scRNA-seq experiment 
Cluster A Cluster B Cluster C Cluster D Cluster E 
Mel53 Mel58 Mel60 Mel67 Mel75 
Mel81 Mel65 Mel89 Mel72  
Mel82 Mel71  Mel80  
Mel84 Mel74  Mel94  




Table S7. Clusters of biospecimens with similar single-cell profiles in ccRCC mass cytometry experiment 
Cluster A Cluster B Cluster C Cluster D Cluster E Cluster F Cluster G Cluster H 
rcc11 rcc12 rcc13 rcc15 rcc16 rcc18 rcc2 rcc55 
rcc14 rcc19 rcc26 rcc34 rcc33 rcc20 rcc27  
rcc17 rcc24 rcc32 rcc40 rcc35 rcc21 rcc28  
rcc36 rcc31 rcc37 rcc41 rcc46 rcc22 rcc29  
rcc42 rcc39 rcc4 rcc43  rcc23 rcc30  
rcc45 rcc5 rcc59 rcc44  rcc3 rcc38  
rcc56 rcc51 rcc64 rcc48  rcc50 rcc75  
rcc57 rcc76 rcc65 rcc53  rcc52 rcc81  
rcc58 rcc9  rcc54  rcc72   
rcc6   rcc60  rcc74   
rcc68   rcc62  rcc77   
rcc69   rcc63  rcc8   
rcc71   rcc67     
rcc73   rcc7     
rcc80   rcc70     
   rcc78     
   rcc79     
   rcc82     
 
